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8Abstract
The rare inherited disease congenital chloride diarrhea (CLD) is caused by over 30
different mutations in the solute carrier family 26 member 3 (SLC26A3 alias DRA) gene
on chromosome 7q22.3-31.1. SLC26A3 encodes  for  an  apical  epithelial  Cl-/HCO3-
exchanger, the intestinal loss of which leads to profuse Cl--rich diarrhea, and a tendency to
hypochloremic and hypokalemic metabolic alkalosis. Although untreated CLD is usually
lethal in early infancy, the development of salt substitution therapy with NaCl and KCl in
the late 1960s made the disease treatable. While the salt substitution allows normal
childhood growth and development in CLD, data on long-term outcome have remained
unclarified.
One of the world’s highest incidences of CLD—1:30 000 to 1:40 000—occurs in
Finland, and CLD is part of the Finnish disease heritage. We utilized a unique sample of
Finnish patients with the homozygous V317del genotype for CLD to characterize the
long-term outcome of the disease.  Another purpose of this study was to search for novel
manifestations of CLD based on the expression of SLC26A3 in the sweat gland and male
seminal vesicle.
Clinical analysis of long-term outcome was performed on a sample of 36 patients (ages
10-38; median 21), comprising 80% of the Finnish patients aged over seven years. Of
them, eight adult males participated in the clinical assessment of fertility as well.
Additionally,  the  data  on  one  deceased  Swedish  patient  with  end-stage  renal  disease
(ESRD) and renal transplantation were included in the analysis of CLD-associated renal
injury. We searched for expression of the SLC26A3 protein, in relation to other ion
transporters, in the tissues of the human male reproductive tract and in the human kidney.
Moreover,  we  performed  a  pilot  trial  with  oral  butyrate  in  five  patients  to  find  whether
butyrate is effective therapy for the diarrheal symptoms of CLD.
This study shows that the long-term outcome of treated CLD is favorable. Almost all
patients rated their general state of health as excellent or good, and few found the diarrheal
symptoms of CLD disturbing. In untreated or poorly treated cases, however, chronic
contraction and metabolic imbalance may lead to renal injury, and even to ESRD. The
relatively high incidence (28%) of chronic kidney disease in our series underlines the
importance of early diagnostics, sufficient salt substitution, and regular follow-up of CLD.
Our results demonstrate, for the first time, a low-level expression of SLC26A3 mRNA and
protein in the human kidney. Although SLC26A3 may play  a  minor  role  in  homeostasis,
post-transplant recurrence of renal changes undoubtedly shows the unlikelihood of direct
transporter modulation in the pathogenesis of CLD-related renal injury.
This study reveals novel manifestations of CLD. These include an increased risk for
hyperuricemia, inguinal hernias, and probably for intestinal inflammation. The most
notable finding of this study is CLD-associated male subfertility. This involves a low
concentration of poorly motile spermatozoa with abnormal morphology, high seminal
plasma Cl- with a low pH, and a tendency to form spermatoceles. Together with a finding
of high sweat Cl- in CLD, this study provides novel data on extraintestinal actions of the
SLC26A3 gene, both in the male reproductive tract and the sweat gland.
9SLC26A3 immunoexpression appeared at multiple sites of the male reproductive tract:
in elongating spermatids, efferent ducts of the testis, ductus epididymis, and seminal
vesicle. That the expression of SLC26A3 arose in part together with the main interacting
proteins—cystic fibrosis transmembrane conductance regulator (CFTR) and
Na+-H+-exchanger 3 (NHE3)—suggests novel sites for the cooperation of these proteins.
SLC26A3 is  therefore  likely  to  promote  electroneutral  absorption  of  NaCl  together  with
NHE3  and  to  modulate  HCO3- secretion  together  with  CFTR  in  the  human  male
reproductive tract. As evidence of the importance of these actions, defects occurring in
any of these transporters are associated with reduced male fertility.
Options to resolve the diarrheal symptoms of CLD have been limited. Unfortunately,
our  pilot  trial  indicated  the  inefficacy  of  oral  butyrate  as  well.  As  the  responses  to  oral
butyrate were variable, however, factors other than the SLC26A3 genotype only are likely
to account for butyrate’s ability to modulate intestinal electrolyte transport in CLD.
In conclusion, early diagnosis and sufficient salt substitution therapy with NaCl and
KCl provide a favorable long-term outcome in CLD. In non-optimally treated disease,
however, risk for renal involvement arises. Of the novel manifestations, the major issues
in clinical management are male subfertility and spermatoceles, resulting from the
defective Cl-/HCO3- exchange in the male reproductive tract. Fortunately, normal
spermatogenesis is likely to make artificial reproductive technologies to treat infertility—
and even make unassisted reproduction—possible.
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Abbreviations
A adenine
aa amino acid
AGE acute gastroenteritis
AE1 anion exchanger 1
AMRC apical mitochondria-rich cell
AQP aquaporin
AR androgen receptor
ATPase adenosine triphosphatase
AZF azoospermia factor
BMI body mass index
bp base pair
C cytosine
Ca2+ calcium ion
CAII carbonic anhydrase II
cAMP cyclic adenosine monophosphate
CBAVD congenital bilateral absence of the vas deferens
CCD cortical collecting duct of the kidney
cDNA complementary deoxyribonucleic acid
CF cystic fibrosis
CFTR cystic fibrosis transmembrane conductance regulator
CKD chronic kidney disease
Cl- chloride ion
CLD congenital chloride diarrhea
CNF congenital nephrotic syndrome
CNT connecting tubule of the kidney
CPITN community periodontal index of treatment needs (dentistry)
Cr-EDTA chrome ethylenediaminetetraacetic acid
DAB diaminobenzidine
DMFS decayed, missed, filled surfaces of teeth index (dentistry)
DNA deoxyribonucleic acid
DRA down-regulated in adenoma
DTDST diastrophic dysplasia sulphate transporter
E3KARP NHE3 kinase A regulatory protein
ECG electrocardiography
ED efferent ducts of the testis
ENaC epithelial sodium channel
ER estrogen receptor
ESRD end-stage renal disease
FSH follicle stimulating hormone
G guanine
GAPDH glyceraldehyde 3-phosphate dehydrogenase, a housekeeping gene
GFR glomerular filtration rate
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H+ hydrogen ion
HCO3- bicarbonate ion
IgG immunoglobulin G
IVF in vitro fertilization
IVS8-T intron 8 polythymidine tract
K+ potassium ion
KCl potassium chloride
Mg2+ magnesium ion
mRNA messenger ribonucleic acid
LH luteinizing hormone
Na+ sodium ion
NaCl sodium chloride
NH4Cl ammonium chloride
NHE Na+/H+ exchanger
NHERF Na+/H+ exchanger regulatory factor
NKCC1 Na+-K+-2Cl- cotransporter
NMIgG normal mouse IgG fraction
NRIgG normal rabbit IgG fraction
OMIM online Mendelian inheritance in man
p short arm of a chromosome
PAT1 putative anion transporter 1
PCR polymerase chain reaction
PDZ postsynaptic density protein PSD95, the Drosophila homologue Disc-large,
and the tight junction protein ZO-1
PDZK1 PDZ domain protein kidney 1
Pi phosphate ion
PKA protein kinase A
q long arm of a chromosome
R domain regulatory domain
RNA ribonucleic acid
RT-PCR reverse transcriptase polymerase chain reaction
SCFA short-chain fatty acid
SD standard deviation
SLC26 solute carrier family 26
SLC26A solute carrier family 26 member
SPSS Statistical Package for Social Sciences
STAS sulphate transporter and anti-sigma antagonist
T thymidine
TBST tris-buffered saline with Tween
UTI urinary tract infection
V-ATPase vacuolar proton-transporting ATPase
WHO World Health Organization
The gene names are in italics and protein names capitalized.
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Introduction
One of the top ten causes of death worldwide is diarrhea, claiming millions of lives
annually. In the developing countries, diarrhea is associated with poverty and
contaminated water supplies. In the more affluent countries, diarrhea is rarely lethal if
treated with adequate fluid replacement therapy. Diarrhea still is, however, one of the
main causes for pediatric emergency visits worldwide and is responsible for one-fourth of
the deaths in children under five years (Kosek et al. 2003).
Although congenital chronic diarrheas are rare and often difficult to diagnose and
manage, they provide important models for understanding the basic pathophysiological
mechanisms of diarrhea. Among these diarrheal disorders are congenital sodium diarrhea
(Booth et al. 1985, Holmberg and Perheentupa 1985), congenital sucrase-isomaltase
deficiency (Ouwendijk et al. 1996), congenital glucose-galactose malabsorption (Martin et
al. 1996), and congenital lactase deficiency (Kuokkanen et al. 2006).
In 1945, two simultaneous case reports described a novel disease called congenital
alkalosis with diarrhea (Darrow 1945, Gamble et al. 1945). In this disorder with alkalosis,
the other major feature was a high concentration of fecal Cl-. Two decades later, alkalosis
turned out actually to be a feature secondary to the Cl--rich diarrhea (Perheentupa et al.
1965, Launiala et al. 1968). Familial enrichment of the cases in Finland resulted in
establishment of the inherited nature of the disease, which was called familial chloride
diarrhea (Perheentupa et al. 1965). This disease was added, with the name “congenital
chloride diarrhea” (CCD or CLD), as the ninth rare disorder to the entity of the Finnish
disease heritage (Norio et al. 1973).
In Finland, finding patients with CLD provided the basis for both the clinical
characterization of the disease and therapeutic trials. The life-saving therapy, salt
substitution with NaCl and KCl, was introduced in Finland in the late 1960s. Thereafter, it
has been used worldwide to prevent metabolic imbalance and to allow normal childhood
growth and development in CLD (Holmberg et al. 1977a).
Although  cases  with  CLD  emerge  worldwide,  most  of  the  clinical  reports,  and
especially those among larger series of patients, originate in Finland. As CLD is such a
rare disease, Finnish clinical experience has provided valuable data for physicians and
patients worldwide. Due to the lethality of CLD until the late 1960s, the long-term
outcome of CLD has remained unclarified. Meanwhile, the identification of the genetic
defect behind CLD (Hoglund et al. 1996b) and the discovery of over 30 different
mutations in this solute carrier family 26 member 3 (SLC26A3) gene (Makela et al. 2002)
have elucidated the underlying pathophysiological mechanisms of CLD. Interestingly,
expression of SLC26A3 messenger RNA (mRNA) or protein appears not only in the
intestine but also in the sweat gland, testis, and male seminal vesicle (Hoglund et al.
1996b, Haila et al. 2000). When combined with the preliminary clinical evidence of male
subfertility in CLD, these data prompted us to hypothesize that CLD involves
extraintestinal manifestations. The main purpose of this study was to characterize the
long-term prognosis of CLD and to reveal whether the extraintestinal expression of
SLC26A3 is associated with any pathological features when it is disrupted in CLD.
13
Review of the literature
1 Clinical picture of CLD
1.1 Clinical symptoms
The only prenatal sign of CLD is polyhydramnios due to intrauterine onset of watery
diarrhea. Other clear hallmarks of CLD include preterm birth, lack of meconium, and
abdominal distention resembling that of intestinal obstruction (Perheentupa et al. 1965,
Launiala et al. 1968, Holmberg et al. 1977a). The main feature of CLD, acidic Cl--rich
diarrhea, leads to excessive loss of fluid and salts immediately after birth, and further to
weight loss, dehydration, and jaundice (Holmberg et al. 1977a). The first signs of salt
depletion in CLD, hyponatremia and hypochloremia, are soon after accompanied by
hypokalemic metabolic alkalosis. If untreated, this metabolic imbalance, together with
severe dehydration, is lethal even during the first weeks or months of life (Holmberg
1986).
1.2 Diagnosis of CLD
CLD diagnosis is based on its typical clinical picture and a high concentration of fecal Cl-,
exceeding 90 mmol/l after correction of the fluid and electrolyte depletion (Holmberg
1986). Although genetic testing for CLD is possible (See Section 2), the simple
measurement of fecal Cl- is still sufficient to confirm CLD diagnosis.
Antenatal  suspicion  of  CLD  arises  due  to  polyhydramnios.  Even  at  the  end  of  the
second trimester, ultrasonic investigation of a fetus with CLD reveals dilated intestinal
loops (Kirkinen and Jouppila 1984, Groli et al. 1986, Poggiani et al. 1992). Despite the
intrauterine onset of diarrhea, concentrations of electrolytes in the amniotic fluid are
normal (Holmberg et al. 1977a). Some other abnormalities, e.g., increased concentrations
of alpha-fetoprotein, may be measurable, but without clinical significance
(Hartikainen-Sorri et al. 1980).
Neonatally, the fluid-filled intestinal loops in the abdominal X-ray may result in a
suspicion of intestinal obstruction and unnecessary surgery (Langer et al. 1991). In
addition, differential diagnosis of CLD includes other inherited diarrheas such as
congenital sodium diarrhea (Booth et al. 1985, Holmberg and Perheentupa 1985), glucose-
galactose malabsorption (Martin et al. 1996), and congenital sucrase-isomaltase deficiency
(Ouwendijk et al. 1996). In these diseases and in other secretory diarrheas, alkaline feces
exclude the possibility of CLD (Holmberg 1986).
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1.3 Therapeutic approaches
The early findings of the intestinal Cl-/base exchange defect provided the basis for
therapeutic trials (Darrow 1945, Gamble et al. 1945, Perheentupa et al. 1965).
Replacement of the intestinal loss of fluid and salts was tested with different combinations
of  salts  such  as  KCl,  NaCl,  or  NH4Cl  (Perheentupa  et  al.  1965).  Of  these,  KCl  therapy
maintained the normal concentrations of serum electrolytes, but slight alkalosis and
Cl--free urine remained (Pasternack et al. 1967). Moreover, the metabolic imbalance
during the KCl therapy was associated with multiple renal changes: juxtaglomerular
hyperplasia, hyalinized glomeruli, nephrocalcinosis, or vascular changes (Pasternack and
Perheentupa 1966, Pasternack et al. 1967). Combination therapy with NaCl and KCl,
however, reversed those renal changes partially and offered protection from the renal
involvement during childhood (Holmberg et al. 1977b).
The oral subsitution therapy recommended is a solution of 1.8% NaCl and 1.9% KCl.
After  intravenous  administration  in  early  infancy,  the  salt  substitution  is  peroral  and
involves  2  to  5  daily  doses.  The  salts  are  diluted  either  in  a  large  amount  of  water  for
several days of use or diluted one dose at a time in a glass of water (Holmberg 1978,
Holmberg 1986). The optimal dosage of Cl- ranges from 6 to 8 mmol/kg/day in infants,
and from 3 to 4 mmol/kg/day in older patients. Adequate excretion of Cl- into the urine, in
addition  to  normal  electrolyte  and  acid-base  status,  confirms  the  sufficiency  of  salt
substitution (Holmberg et al. 1977a, Holmberg 1986).
Although the salt substitution inhibits development of hypochloremic and hypokalemic
metabolic alkalosis in CLD, diarrhea is persistent. Due to the watery stools, a common
problem in these children is soiling (Holmberg 1986). High-dose therapy with
glucocorticoids reduces the diarrhea but is inapplicable for long-term use because of
adverse effects (Perheentupa et al. 1965). Several more easily applicable agents—
including anion exchange resins (Pearson et al. 1973), prostaglandins (Minford and Barr
1980, Holmberg and Perheentupa 1982), and spironolactone (Asano et al. 1994)—have
failed to resolve the diarrheal symptoms.
One case report proposed that an effective diarrhea-reducing therapy is oral
administration of the proton-pump inhibitor omeprazole (Aichbichler et al. 1997). Another
study in patients with optimal salt substitution disproved the efficacy of omeprazole,
however (Hoglund et al. 2001a). During this study, a case report showed that oral
administration of a short-chain fatty acid (SCFA) butyrate normalized stool volume and
consistency in an 11-year-old Italian patient (Canani et al. 2004). Thus far, the only agent
with evidence for a moderate but temporary diarrhea-reducing effect, up to 30 to 40%, is
cholestyramine. It binds bile acids, reducing intestinal secretion not only in bile-acid
induced diarrhea but also, by some unclarified mechanism, in CLD (Brocklehurst and
Walker 1978, Holmberg et al. 1982).
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1.4 Complications of CLD
During childhood, combination therapy with NaCl and KCl protects from the common
complications of untreated CLD: constant dehydration and hypoelectrolytemia, retarded
growth and development, activation of the renin-aldosterone system, and renal
involvement (Pasternack and Perheentupa 1966, Pasternack et al. 1967, Holmberg et al.
1977a, Holmberg 1986). Rare CLD complications include volvulus, mental subnormality,
non-specified colitis, and hyperuricemia (Holmberg 1986, Nuki et al. 1991, Kagalwalla
1994). Moreover, CLD involves teeth anomalies (deciduous teeth hypoplasia and other
enamel defects) and an increased resistance to dental caries, the latter probably being due
to the oral salt solutions (Myllarniemi and Holmerg 1975, Kerebel et al. 1984). Except for
one study suggesting that the mutations for CLD predispose to intestinal cancer
(Hemminki et al. 1998), reports of CLD-associated malignancies are non-existent.
Although untreated CLD is usually lethal in early infancy, and the known
complications are associated mostly with untreated disease, several patients have survived
for months or even years without a correct diagnosis. One such patient with recurrent
episodes of ileus survived undiagnosed for 21 years (Pearson et al. 1973). Even in Finland,
a patient born in the 1990s had his CLD diagnosed at age 5, due to misinterpretation of the
diarrheal symptoms as food allergy (Leskinen 1996). In these few patients, a potential
contributor to survival is increased consumption of dietary salt. On the other hand,
survivors with untreated CLD seem to develop a less severe, chronic course of the disease,
the identification of which may be highly challenging (Holmberg 1986). Their persistent
diarrhea is, however, often associated with a special vulnerability to dehydration and
severe hypoelectrolytemia both during the episodes of gastroenteritis or during other
common infections of childhood (Holmberg et al. 1977a).
1.5 Early data on CLD pathophysiology
The very first reports on CLD suggested that the underlying cause of the acidic Cl--rich
diarrhea is a defect in intestinal Cl-/base transport (Darrow 1945, Gamble et al. 1945).
First, what was unclear was whether the primary defect in CLD was increased secretion or
reduced absorption of Cl-. After localization of the defect in the terminal ileum and colon
(Launiala et al. 1968, Turnberg 1971), perfusion studies demonstrated the basic defect in
the Cl-/HCO3- exchange (Turnberg 1971, Bieberdorf et al. 1972, Pearson et al. 1973).
Moreover, the low fecal HCO3- and reduced colonic absorption of Na+ in CLD provided
initial data on coupled Na+/H+ exchange in the colon. Further perfusion studies revealed
that  inhibition  of  NaCl  absorption  and  fecal  acidity  induce  the  osmotic  diarrhea  in  CLD
(Holmberg et al. 1975).
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2 Genetic basis of CLD
2.1 Geographical distribution of CLD
2.1.1 The Finnish disease heritage and CLD
The very first report on CLD in Finland revealed that the disease is inheritable
(Perheentupa et al. 1965). The familial occurrence of cases allowed identification of both
the autosomal recessive inheritance trait and uneven geographical distribution of CLD
(Norio et al. 1971). These families originated almost exclusively in eastern Finland. In this
region, the population history involves a small number of settlers who inhabited
northeastern Finland in the 16th century. Thereafter, genetic isolation with local founder
effects resulted in the enrichment of many rare disease-causing alleles in this
subpopulation. In this unique genetic pool, not only the major mutation for CLD but also
for many other rare diseases enriched, forming the basis for the entity called the Finnish
disease heritage (Nevanlinna 1972, Norio et al. 1973). This series of disorders involves
almost 40 Mendelian diseases which are very rare elsewhere and which have expanded in
the Finnish population through single founder mutations (de la Chapelle 1993). That the
Finnish gene pool is less variable than those of the general European or Baltic populations
provides possibilities for genetic studies in both monogenic and polygenic disorders (de la
Chapelle 1993, Service et al. 2006).
2.1.2 Other populations with CLD
The first diagnosed cases with CLD were Americans partly of Italian descent (Darrow
1945, Gamble et al. 1945). Later, more than 250 cases with CLD have been reported
worldwide. Although single cases arise from all continents, CLD geographical distribution
is uneven (Figure 1).
One-fifth  of  all  reported  CLD  patients  originate  from  Finland,  where  incidence  is
around 1:30 000 to 1:40 000 (Hoglund et al. 1998a). Other populations with a higher than
average incidence are Polish (1:200 000), Kuwaiti, and Saudi Arabian. In the countries
around the Persian Gulf, and especially in Kuwait, local estimates of incidence total as
high as 1:3 200 to 1:5 000 due to consanguineous marriages (Tomaszewski et al. 1987,
Lubani et al. 1989, Shaltout et al. 1989, Abdullah et al. 1990, Kagalwalla 1994, Kierkus et
al. 1995, Badawi et al. 1998, Kere et al. 1999). The exact figures for incidence at
population level remain, however, unascertainable.
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Africa
Poland
Other European countriesSaudi Arabia
Kuwait
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South America Australia
Finland
Figure 1 Geographical distribution of reported cases of CLD based on a survey in the PubMed
database (www.pubmed.gov).
2.2 Identification of the CLD gene
The CLD locus was originally mapped to 7q31, close to the cystic fibrosis transmembrane
conductance regulator (CFTR) gene (Kerem et al. 1989, Bear et al. 1992), with candidate-
gene-based linkage analysis (Kere et al. 1993). Further mapping of the CLD locus allowed
the identification of four regional candidate genes, the most interesting of which was
down-regulated in adenoma (DRA) (Hoglund et al. 1995, Hoglund et al. 1996a).
Previously, this gene had been cloned as a potential tumor suppressor gene based on its
abundant expression in the colon but its absence from colonic adenomas and
adenocarcinomas (Schweinfest et al. 1993, Taguchi et al. 1994). Support for the role of
DRA in CLD came from the fact that the protein encoded by this gene was an intestine-
specific sulfate transporter (Silberg et al. 1995).
Identification of the homozygous V317del mutation in the DRA gene among Finnish
patients, and H124L and 344delT mutations in the Polish patients showed that DRA
mutations are responsible for CLD (Hoglund et al. 1996b).
2.3 CLD gene in the SLC26 transporter family
The DRA gene comprises 21 exons and spans 37.7 kb on the minus strand of chromosome
7q22.3-31.1 (Haila et al. 1998, Kent et al. 2002). The translation initiation codon is
located in exon 2 and the termination codon in exon 21. The protein product of DRA is an
apical transmembranic protein with 764 amino acids, involving 14 probable hydrophobic
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membrane-spanning domains and a sulphate transporter and anti-sigma antagonist (STAS)
domain covering amino acids 525 to 720 in the cytoplasmic COOH-terminal end
(Figure 2) (Byeon et al. 1996, Bairoch et al. 2005). The DRA protein is a Cl-/HCO3-
exchanger which acts in conjunction with other epithelial ion transporters, modulating net
transport in the epithelial cells (See Section 3) (Melvin et al. 1999, Moseley et al. 1999,
Jacob et al. 2002, Lamprecht et al. 2006).
The  very  first  studies  of DRA showed notable protein homology with the human
diastrophic dysplasia sulphate transporter (DTDST) gene (Hastbacka et al. 1994) and
with a number of genes of the sulfate permease family in other species. Later, the DRA
gene was included as a third member in the novel human solute carrier family 26 (SLC26),
which involves 11 structurally homologous anion exchangers (Table 1) (Mount and
Romero 2004, Kere 2006). Of these, several are associated in a homozygous form with
rare human diseases. SLC26A2 mutations cause autosomal recessive bone and cartilage
disorders: diastrophic dysplasia (OMIM 222600), achondrogenesis type IB (OMIM
600972), atelosteogenesis type II (OMIM 256050), and multiple epiphyseal dysplasia
(OMIM 226900) (Hastbacka et al. 1994, Hastbacka et al. 1996, Superti-Furga et al. 1996,
McKusick 2007). SLC26A3 (alias DRA) mutations cause CLD (OMIM 214700) (Hoglund
et al. 1996b, McKusick 2007). SLC26A4 mutations cause Pendred syndrome (OMIM
274600), accounting for around 10% of the cases with hereditary deafness, and enlarged
vestibular aqueduct syndrome (OMIM 600791) (Everett et al. 1997, Li et al. 1998,
McKusick 2007). SLC26A5 mutations are associated with autosomal recessive non-
syndromic neurosensory deafness (Zheng et al. 2000, Liu et al. 2003). Both the SLC26A2-
associated diastrophic dysplasia and SLC26A3-associated CLD are, through single founder
mutations, part of the Finnish disease heritage (Hoglund et al. 1996b, Hastbacka et al.
1999, Norio 2003).
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Figure 2 Predicted structure of the human DRA (alias SLC26A3) protein and localization of
the Finnish founder mutation V317del for CLD. The COOH-terminal cytoplasmic tail
includes two protein interaction motifs (See Section 3.3): the STAS domain
comprising amino acids 525 to 720, and the PDZ interaction motif involving four
terminal amino acids.
19
Table 1 Characteristics of SLC26 family members.
Gene (alias) Genbank Chromosome Expression Disease Reference
SLC26A1 (Sat-1) NM_022042 4p16.3 Liver, kidney,
brain, muscle
- (Bissig et al. 1994)
SLC26A2 (DTDST) NM_000112 5q31-34 Widespread Chondrodysplasias (Hastbacka et al. 1994)
SLC26A3 (DRA, CLD) NM_000111 7q22.3-31.1 Intestine, testis,
seminal vesicle,
sweat gland
Congenital
chloride diarrhea
(Schweinfest et al. 1993,
Hoglund et al. 1996b,
Haila et al. 2000)
SLC26A4 (Pendrin) NM_000441 7q31 Thyroid, kidney,
cochlea
Pendred syndrome
and enlarged
vestibular aqueduct
syndrome
(Everett et al. 1997,
Li et al. 1998)
SLC26A5 (Prestin) NM_198999 7q22 Cochlea Non-syndromic
deafness
(Zheng et al. 2000,
Liu et al. 2003)
SLC26A6 (PAT-1) NM_022911 3p21 Kidney, pancreas,
small intestine
Mouse urolithiasis (Lohi et al. 2002a,
Wang et al. 2002,
Jiang et al. 2006)
SLC26A7 NM_052832 8q22.2 Kidney, stomach - (Lohi et al. 2002a,
Petrovic et al. 2003)
SLC26A8 (Tat1) NM_052961 6p21.3 Testis, brain - (Lohi et al. 2002a,
Vincourt et al. 2003)
SLC26A9 NM_052934 1q32 Lung, kidney - (Lohi et al. 2002a,
Sindic et al. 2007)
SLC26A10 NM_133489 12q13 Pseudogene - (Lohi et al. 2002a)
SLC26A11 NM_173626 17q25 Widespread - (Lohi et al. 2002a,
Vincourt et al. 2003)
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2.4 Expression pattern and mutation spectrum of the SLC26A3 gene
In both humans and rodents, expression of SLC26A3 mRNA and protein emerges in the
absorptive surface epithelium of the small intestine, especially in the ileum but also in the
duodenum, and in the surface epithelium of the colon (Figure 3). In the intestinal crypts,
the  signal  is  lacking  (Hoglund  et  al.  1996b,  Jacob  et  al.  2002).  In  the  human  male
reproductive tract, a very weak signal for SLC26A3 mRNA appears in the testis (Hoglund
et al. 1996b). Although the first study showed abundant expression of SLC26A3 mRNA in
the prostate, future studies found the SLC26A3 protein actually in the epithelium of the
human male seminal vesicle (Hoglund et al. 1996b, Haila et al. 2000). Moreover,
SLC26A3 is expressed in the epithelium of the human sweat gland (Haila et al. 2000). In
cell cultures, expression of SLC26A3 appears in epithelial cells derived from the
pancreatic duct (Greeley et al. 2001) and the trachea (Wheat et al. 2000).
Regarding diseases, expression of SLC26A3 mRNA often is decreased in ulcerative
colitis, but data on protein expression are inconsistent (Yang et al. 1998, Haila et al. 2000,
Lohi et al. 2002b). In intestinal adenomas and adenocarcinomas, expression of SLC26A3
is significantly down-regulated or even undetectable (Schweinfest et al. 1993, Antalis et
al. 1998).
Over 30 different mutations—including the founder mutations of Finland, Poland, and
Arabic countries—cause CLD (Table 2) (Hoglund et al. 1998a, Makela et al. 2002). The
Finnish founder mutation V317del (Figure 2), in-frame deletion of a valine at codon 317,
originates from a small northeastern subpopulation from 400 to 500 years ago, presumably
through only one ancestor (Norio et al. 1973, de la Chapelle 1993, Hoglund et al. 1996b).
The carrier frequency of this Finnish major mutation is around 1% in eastern Finland, but
significantly lower in southwestern parts of the country (Hoglund et al. 1996b).
The wide spectrum of mutations suggests that novel mutations in the CLD gene are
relatively common. At least codon 120, found to harbor the mutation G120S in three
independent families, is one of the mutational hot-spots. Despite the various types of
mutations and their wide distribution in different regions of the SLC26A3 gene, evidence
of genotype–phenotype differences in CLD is non-existent (Makela et al. 2002). Even the
identical genetic background of CLD may, however, result in variable types of clinical
courses if the diagnosis is delayed or salt substitution insufficient (Holmberg et al. 1977a,
Hoglund et al. 2001a).
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Table 2 SLC26A3 mutations, founder mutations (gray), and polymorphisms.
Mutation Exon Nucleotide
change
Effect Codon Protein
product
Patient origin
G120S 4 358G>A aa change 120 conserved Poland, Sweden, Norway
H124L 4 371A>T aa change 124 conserved Poland, Sweden (Polish
ancestry)
P131R 5 392C>G aa change 131 partly conserved USA
S206P 6 616T>C aa change 206 conserved Netherlands (Morocco
ancestry)
S438P 12 1312T>C aa change 438 conserved USA
D468V 12 1403A>T aa change 468 conserved Poland
Q495H 13 1484A>C aa change 495 partly conserved Italy
L496R 13 1487T>G aa change 496 partly conserved Hong Kong
T510M 14 1529C>T aa change 510 conserved USA (Zimbabve origin)
I544N 15 1631T>A aa change 544 conserved Vietnam
A547E 15 1640C>A aa change 547 partly conserved Italy
S654P 15 1960T>C aa change 654 conserved USA (Zimbabve origin)
G187X 5 559G>T stop codon 187 truncated Arabic, UK (Arabic origin)
Y305X 8 915C>A stop codon 305 truncated Poland
Q436X 11 1306C>T stop codon 436 truncated Netherlands
W462X 12 1386G>A stop codon 462 truncated UK
145-157del13 3 frameshift 49 truncated Belgium (Togo ancestry)
344delT 4 frameshift 115 truncated Poland, Finland
614delT 6 frameshift 205 truncated USA
3.5 kb deletion intron 6-8 frameshift - deleted Japan
V317del 8 in-frame loss 317 non-functional Finland, Sweden (Finnish
origin)
1342-1343delTT 12 frameshift 448 truncated Japan
1516delC 14 frameshift 505 truncated Poland
1548-1551delAACC 14 frameshift 516 truncated Poland
Y527del 14 in-frame loss 527 deleted Poland
1609delA 15 frameshift 537 truncated Canada
1758delG 16 frameshift 586 truncated Italy (Morocco ancestry)
1.7 bp deletion intron 17-18 frameshift - truncated Italy
2116delA 19 frameshift 706 truncated Finland
177-178insC 3 frameshift 60 truncated USA
268-269insAA 3 frameshift 90 truncated Hong Kong
I675-676insATC 18 in-frame addition 676 non-functional Poland
2104-
2105delGGins29
19 in-frame
substitution
703 non-functional Norway
IVS5-2A>G intron 5 splice defect truncated Canada
IVS5-1G>T intron 5 splice defect truncated USA
IVS11-1G>A intron 11 splice defect truncated Poland
IVS12-1G>C intron 12 splice defect truncated Germany (Palestine ancestry)
IVS13-2delA intron 13 splice defect truncated Kuwait
Polymorphisms
C307W 8 921T>G aa change 307 normal function Finland, USA, Sweden
1299G>A 11 1299G>A no change 433 normal USA, Kuwait, UK, Japan,
Sweden
1314C>T 12 1314C>T no change 438 normal Kuwait
R554Q 15 1661G>A aa change 554 non-conserved Japan
References: (Hoglund et al. 1996b, Hoglund et al. 1998b, Hoglund et al. 2001b, Makela et al. 2002, Cardillo 2005). aa=amino acid. bp=base pair.
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3 Pathophysiology of CLD
3.1 Basic structure of the intestine
The intestine comprises two parts, the small and large intestine, with different structural
and functional properties. The small intestine involves the duodenum, jejunum, and ileum.
The colon, or the large intestine, comprises the cecum and ascending, transverse,
descending, and sigmoid colon (Gartner and Hiatt 1997). The parts of the four-layered
intestinal wall are the mucosa, submucosa, muscularis externa, and serosa. The mucosa is
further divided into the epithelium, a connective tissue layer called the lamina propria, and
a smooth muscle layer called the muscularis mucosa. In the intervillar spaces of the small
intestine and in the basal foldings of the colon, the lamina propria forms the core of the
crypts of Lieberkühn (Figure 3) (Gartner and Hiatt 1997).
The main structural difference between the small intestine and colon is the folded
epithelium of the small intestine, involving villi and microvilli to increase the absorptive
surface  of  the  epithelium.  Enterocytes,  the  major  cell  population  of  the  intestinal
epithelium, form a simple columnar layer of cells which are responsible for the absorptive
actions of the intestine. As the life-span of enterocytes is short, around 3 to 5 days,
continuous maturation of the regenerative cells in the basal crypts and migration of these
cells into the surface epithelium occurs. In addition to regenerative cells, the proliferation
zone of the crypts of Lieberkühn involves undifferentiated Cl- secreting epithelial cells,
and enteroendocrine cells which secrete hormones such as cholecystokinin, secretin, and
gastric inhibitory peptide into the intestinal lumen. Mucus-secreting goblet cells appear
throughout the intestine, mostly in the surface epithelium. In the basal crypts of the small
intestine, Paneth cells act as an essential part of the antimicrobial barrier by releasing
antimicrobial peptides into the luminal space (Figure 3) (Gartner and Hiatt 1997).
Figure 3 Absorptive surface epithelium of the small intestine (left) involves finger-like villi,
whereas the surface epithelium of colon (right) forms foldings into the lamina
propria. Intestinal absorption, including the SLC26A3-mediated transport, occurs
mostly through the surface epithelium, and intestinal secretion arises from crypts.
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3.2 Main principles of intestinal absorption and secretion
Both the small and large intestine possess several essential mechanisms for absorption and
secretion of electrolytes and fluid (Turnberg 1970, Turnberg et al. 1970). These
mechanisms vary depending on the segment of the intestine. A simplified model is that
small-intestinal secretion arises from crypts and absorption from villi. In the colon, crypts
exhibit both secretory and absorptive actions, whereas the surface epithelium is absorptive
only (Figure 3) (Field 2003). Additionally, the epithelium of the colon is less permeable
than that of the small intestine, making active transport mechanisms crucial.
Intestinal fluid absorption is secondary to Na+ absorption, which is regulated by
several ion transporters of the epithelial brush border, each depending on the segment of
intestine (Field 2003).
In  the  upper  small  intestine,  Na+ absorption is coupled with absorption of organic
solutes, i.e., amino acids, oligopeptides, and sugars (Schultz et al. 1966). Absorption of
organic solutes and salts and their further transport from enterocytes to the lateral
intercellular space forms the osmotic gradient for paracellular water absorption. This
coupled absorption of Na+ together  with  amino  acids  and  sugars  forms  the  basis  for
management of acute diarrheas with oral rehydration therapy (Schultz et al. 1966).
In  the  jejunum,  Cl- movement is passive, and electroneutral Na+ absorption occurs
through the Na+/H+ exchangers (NHEs). Of these, the isoforms NHE2 and NHE3 are
expressed in the apical epithelium of the small intestine and colon (Hoogerwerf et al.
1996, Zachos et al. 2005). NHE3 seems, however, to be the most relevant transporter,
since the knock-out mouse exhibits chronic diarrhea (Schultheis et al. 1998). In contrast,
the NHE2 knock-out mouse suffers from gastric dysfunction only, without intestinal
defects  (Miller  et  al.  2002).  The  third  NHE  of  the  intestine,  NHE1,  is  expressed  on  the
basolateral  membrane  of  the  enterocytes.  It  regulates  homeostasis  by  removing  H+ ions
from the cells, thereby affecting the apical secretion of HCO3- as well (Tyagi et al. 2000).
In the ileum and proximal colon, absorption of NaCl occurs predominantly via the
coupled action of NHE3 and Cl-/HCO3- exchangers (Field 2003). The two main Cl-/HCO3-
transporters involved in the anion exchange of the small-intestinal and colonic brush
border are CLD-related SLC26A3 (Hoglund et al. 1996b) and the putative anion
transporter (PAT1) alias SLC26A6 (Table 1) (Lohi et al. 2000). In the small intestine, the
predominant anion transporter is SLC26A6, whereas the major transporter in the ileum
and colon is SLC26A3 (Wang et al. 2002). In addition, several basolateral exchangers
such as the Na+/K+-ATPase and Cl- and K+ channels are necessary for development of the
electrochemical gradient for intestinal absorption. In the distal colon, however, absorption
of Na+ is electrogenic, occurring via an aldosterone-sensitive epithelial Na+ channel
(ENaC) (Canessa et al. 1994).
Short-chain fatty acids (SCFA) produced from the nonabsorbed carbohydrates by
colonic bacteria are involved in the intestinal absorption through several mechanisms such
as apical SCFA/HCO3- and Cl-/SCFA exchange. As the apical SCFA/HCO3- exchange is
linked to the parallel Na+/H+ exchange, absorption of SCFAs and especially that of
butyrate promotes electroneutral NaCl and fluid absorption in the colon (Binder et al.
2005).
24
Intestinal secretion arises from the epithelial crypts and is secondary to anion secretion,
especially that of the Cl- channel CFTR, i.e., the cystic fibrosis transmembrane
conductance regulator (Welsh et al. 1982, Riordan et al. 1989, Schwiebert et al. 1995).
Cyclic AMP (cAMP) stimulates, via protein kinase A (PKA), intestinal secretion by
opening the apical Cl- channel CFTR and the basolateral K+ channel, which together
promote the activity of the basolateral Na+-K+-2Cl- cotransporter (Geck and Heinz 1986,
Greger 2000, Kunzelmann and Mall 2002, Field 2003). CFTR directly mediates not only
Cl- but also HCO3- secretion throughout the intestine (Trezise and Buchwald 1991, Strong
et al. 1994). At least in the small intestine, the CFTR channel is able to modulate intestinal
HCO3- secretion by acting in conjunction with the apical Cl-/HCO3- exchangers of the
SLC26 family (See Section 3.3.2) (Geibel et al. 2000, Field 2003, Lamprecht and Seidler
2006).
In most cases with diarrhea, more than one of the driving forces—osmosis, active
secretion, exudation, or altered motility of the intestine—contribute (Field 2003). In
ulcerative colitis, both the absorption of Na+ and that of Cl- and water are defective. The
underlying cause seems to be the decreased electrogenic Na+ absorption through ENaC in
the distal colon, although the colonic electroneutral NaCl transport, occurring mostly
through NHE3 and SLC26A3, is diminished as well (Sandle 2005).
3.3 Pathophysiological basis of CLD
Although intestinal absorption and secretion form separate entities, they constitute a
complex network of transporters, the regulation of which is essential for both the
absorptive and secretory actions of the intestinal epithelium. Regarding CLD, even early
studies revealed inhibited Na+ absorption, despite the primary defect of the epithelial
Cl-/base exchange (Holmberg et al. 1975). Later studies characterized the basic defect of
CLD as loss of the apical Cl-/HCO3- exchange activity in the ileum and colon (Moseley et
al. 1999). Secondarily, accumulation of Cl- and H+ into the luminal space disrupts
epithelial Na+/H+ transport,  leading  to  intestinal  loss  of  both  NaCl  and  fluid,  and  to  the
profuse diarrhea of CLD. In untreated disease, hypochloremia, hyponatremia, and
dehydration result in activation of the renin-angiotensin system. The resultant
hyperaldosteronism induces Na+ reabsoprtion in the distal colon and especially in the
distal  tubule  of  the  kidney,  resulting  in  the  secondary  K+ depletion  which  leads  to  an
increase in both the hypokalemia and metabolic alkalosis in untreated CLD (Holmberg
1978).
The SLC26A3 protein is the colon’s most essential apical anion transporter. Evidence
for this is the life-threatening diarrheal phenotype of CLD, and recently, existence of
SLC26A3-deficient mice with a diarrheal phenotype closely similar to that of CLD
(Schweinfest et al. 2006). SLC26A3-deficient mice exhibit, however, unique features
uncharacteristic of human CLD. These include significant growth retardation, occasionally
development of prolapsed rectums, and most interestingly, an aberrant growth pattern of
the colonic mucosa with an expanded proliferative zone of colonic crypts and hyperplasia
of the surface epithelium (Schweinfest et al. 2006).
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3.3.1 PDZ interaction coupling SLC26A3 with NHE3
PDZ domains are the most common protein interaction modules of the human genome.
The abbreviation “PDZ” comes from the names of the first three proteins found to
comprise this domain: postsynaptic density protein PSD95, the Drosophila homologue
Disc-large, and the tight junction protein ZO-1. The basic structure of PDZ domains
comprises 90 to 100 amino acids involving two ?-helixes and six ?-sheets which form a
hydrophobic binding site for PDZ motifs (Harris and Lim 2001). In most of the PDZ
adapter proteins, several PDZ domains with variable binding abilities exist with other
common protein interaction domains. Binding of several proteins to one PDZ adapter
protein is therefore likely to allow formation of larger interactive protein networks (Brone
and Eggermont 2005, Lamprecht and Seidler 2006).
In the SLC26A3 protein, the PDZ motif comprises four C-terminal amino acids,
glutamate-threonine-lysine-phenylalanine (ETKF) (Figure 2) (Lamprecht et al. 2002). This
domain is able to bind to several PDZ adapter proteins: NHE3 kinase A regulatory protein
(E3KARP), NHE3 regulatory factor (NHERF), and PDZ domain protein kidney 1
(PDZK1) (Lamprecht and Seidler 2006).
In the ileum and proximal colon, electroneutral NaCl absorption occurs through the
coupled activity of NHE3 and SLC26A3 (Figure 4) (Melvin et al. 1999). Although NHE3-
related human diseases remain non-existent, severe diarrhea in both NHE3 knock-out mice
and in SLC26A3-deficient  humans  and  mice  reveal  the  crucial  role  of  these  proteins.  To
underline the importance of the coupled transport, NHE3 knock-out mice have increased
levels of intestinal SLC26A3 mRNA, and SLC26A3-deficient mice show massive
upregulation of intestinal NHE3 mRNA and protein. In addition, SLC26A3-deficient mice
exhibit significant upregulation of the other Na+ channel, aldosterone-sensitive ENaC, in
the distal colon (Melvin et al. 1999, Schweinfest et al. 2006).
Although an exact model for the interaction between SLC26A3 and NHE3 is lacking,
these proteins are coupled at least via E3KARP, NHERF, and PDKZ1. Most of the knock-
out models for these PDZ adapter proteins show only minor intestinal defects, suggesting
that intestinal networks of transporters rather than single regulators are crucial (Lamprecht
and Seidler 2006). In many diarrheal conditions, the electroneutral NaCl absorption of the
intestine is affected (Kunzelmann and McMorran 2004). It remains unclear, however,
whether endogeneous substances, drugs, or bacterial and viral enterotoxins affect directly
or through PDZ-interacting proteins the activity of NHE3.
In addition to NHE3, other PDZ-interacting proteins may also be of importance for the
function of SLC26A3. For instance, cytosolic carbonic anhydrase II (CAII) is required for
the full SLC26A3-mediated bicarbonate transport in cell cultures. This direct interaction
of SLC26A3 and CAII is, however, unable to stimulate the transport activity of SLC26A3
(Sterling et al. 2002). In the small intestine, SLC26A3 is expressed together with CFTR,
and both these proteins are capable of binding to the PDZ domains of PDZK1. SLC26A3
and CFTR may thus regulate HCO3- secretion in the small intestine, but most probably,
not in the colon (See Section 3.3.2) (Rossmann et al. 2005).
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Figure 4 SLC26A3 is coupled with NHE3 in surface epithelial cells of the colon.
3.3.2 STAS domain coupling SLC26A3 with CFTR
The activation of SLC26A3 is increased in the presence of CFTR, and vice versa. The
basis for this interaction is phosphorylation of the cytosolic regulatory domain, R domain,
of CFTR and its binding to the STAS domain of SLC26A3 (Figure 2) (Aravind and
Koonin 2000, Ko et al. 2002). In addition to this domain interaction, binding of these
proteins to the PDZ adapter proteins facilitates the interaction by some unspecifed
mechanism (Ko et al. 2004).
The early studies showed that the primary defect in cystic fibrosis (CF) is reduced
activity of the Cl- channel CFTR (Kerem et al. 1989, Riordan et al. 1989, Bear et al.
1992). Later studies illustrated, however, that the defective Cl- transport actually results
from the  inability  of  the  mutant  forms  of  CFTR to  activate  the  HCO3- transport through
Cl-/HCO3- exchangers (Lee et al. 1999a, Lee et al. 1999b). That mild phenotypes of CF are
associated with normal Cl- channel activity, but with aberrant HCO3- secretion only, was a
notable finding (Sheppard et al. 1993, Choi et al. 2001a). Further studies showed that
CFTR specifically up-regulates Cl-/HCO3- exchange activity of the SLC26 gene family
members SLC26A3, SLC26A4, and SLC26A6 (Greeley et al. 2001, Ko et al. 2002). The
interaction of these transporters is based on the binding of the R domain of CFTR into the
STAS domains of those SLC26 family members. In addition, this interaction is enhanced
when CFTR is activated by phosphorylation or by some PDZ-interacting proteins (Ko et
al. 2004).
The present model suggests that in the pancreatic duct, for instance, the interaction
between CFTR and SLC26A6 takes place in the proximal part of the duct, whereas in
more distal parts, interaction of CFTR and SLC26A3 occurs (Ko et al. 2004). On the other
hand, the CFTR channel alone is able of secreting both Cl- and HCO3- anions, making a
more complex model than this one probable (Linsdell et al. 1997, Spiegel et al. 2003). The
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regulatory  action  between  CFTR  and  SLC26A3  (Figure  5)  seems  to  be  essential  for
epithelial HCO3- secretion in the tissues where both the transporters are expressed,
meaning at least the small intestine (Moseley et al. 1999, Greger 2000, Jacob et al. 2002,
Rossmann et al. 2005), pancreatic duct (Greeley et al. 2001, Ko et al. 2004), and tracheal
epithelium  (Wheat  et  al.  2000).  The  essential  physical  association  between  CFTR  and
SLC26 transporters requires intact STAS and R domains. As at least two CLD-causing
mutations on the STAS domain of SLC26A3 prevent the activation of CFTR as well,
CFTR may also play a role in the pathogenesis of CLD (Ko et al. 2004).
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Figure 5 SLC26A3 is coupled with CFTR in epithelial cells of the pancreatic duct.
3.3.3 Mutation-associated pathophysiology in CLD
Functional data on mutant forms of SLC26A3 are limited. Regarding the Finnish founder
mutation V317del (Figure 2), the anion exchange activity is lacking despite the normal
levels of SLC26A3 mRNA and protein in the CLD colon (Hoglund et al. 1996b, Melvin et
al. 1999, Moseley et al. 1999). An associated feature of the mutation V317del is a
substitution of tryptophan for cysteine ten codons upstream (C307W), the frequency of
which alone is around 14% in the healthy Finnish population. This C307W variant is, as
expected, compatible with normal anion exchange activity and is therefore considered a
meaningless SLC26A3 polymorphism (Hoglund et al. 1996b, Moseley et al. 1999).
The mouse V317del-homologue mutant V310del is retained in the endoplasmic
reticulum, failing to show any expression on the apical plasma membrane (Ko et al. 2002).
Similar to the human V317del, some other CLD-associated mouse mutants, e.g., L489R
and I668-669ins, are expressed on the plasma membrane. None of the mutants show,
however, any Cl-/HCO3- exchange activity in cell cultures (Ko et al. 2002, Chernova et al.
2003). These findings are in line with the fact that data on genotype-phenotype differences
in CLD are lacking (Makela et al. 2002).
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4 Molecular genetics of male infertility
4.1 Basic structure and electrolyte economy of the male reproductive tract
Mammalian sperm is produced in the seminiferous epithelium of the testis. Testicular
tissue, surrounded by a connective tissue capsule, is divided into hundreds of lobules with
seminiferous tubules. Between these tubules appear septal walls and androgen-secreting
Leydig cells (Holstein et al. 2003).
The seminiferous epithelium (Figure 6) comprises different developmental stages of
spermatogonia, primary and secondary spermatocytes, and spermatids. Between these
maturing cells appear Sertoli cells. They form invaginations and provide both nutrition
and supportive functions for the germ cells. Moreover, Sertoli cells organize the delivery
of mature spermatids to the testicular lumen and secrete various endocrine and paracrine
substances to regulate spermatogenesis (Holstein et al. 2003).
In addition to producing spermatozoa, the seminiferous epithelium of the testis secretes
fluid to the male reproductive tract (Yeung et al. 1991, Holstein et al. 2003). Of this fluid,
as much as 95% is already reabsorbed in the initial zone of the efferent ducts (ED) of the
testis before spermatids pass into the epididymis (Figure 6). Fluid reabsorption in the ED
occurs via a paracellular route and through the water channels of the non-ciliated cells,
whereas the ciliated cells take up other substances by endocytosis (Clulow et al. 1998).
Fluid reabsorption is essential for both sperm concentration and maintenance of the
optimal microenvironment for sperm maturation. During transport through the epididymal
ducts, the composition of sperm is gradually changed by both reabsorptive and secretory
actions before storage in the distal epididymis and vas deferens. The underlying
mechanisms for this fluid reabsorption in both the ED and epididymis are poorly
understood. Regulation of this reabsorption is an unclear process as well, although at least
flow, luminal conditions, and sex steroids contribute (Clulow et al. 1998).
As the fluid reabsorption is coupled to active solute transport, a striking change in the
luminal enviroment of the ED is the decline in concentrations of Na+,  K+, and Cl-. In
rodents, concentrations of Na+ and Cl- decrease from 100 mmol/l in the testis to 25 mmol/l
in the distal epididymis (Jenkins et al. 1980). The subsequent increase in osmolality allows
the shrinkage of epididymal sperm. This sperm volume regulation is a crucial feature for
both sperm morphology and motility. For instance, incubation of sperm with K+ raises
sperm volume and, at the same time, reduces the efficiency of forward progression (Yeung
et al. 2003).
One of the most well-established transporters in the ED is the apical Na+/H+ exchanger
NHE3. In rodents, it is expressed on the apical membrane of the non-ciliated cells
responsible for fluid reabsorption (Bagnis et al. 2001, Kaunisto and Rajaniemi 2002).
Other apical transporters in the mouse non-ciliated cells include the water channel
aquaporin-1 (AQP1) and CFTR (Fisher et al. 1998, Leung et al. 2001a). Although NHE3
is the major transporter for reabsorption, uptake of luminal fluid in the ED is dependent on
movements of both Na+ and Cl-. In this regulated process, a possible apical Cl-/HCO3-
exchanger may be important, acting in parallel with NHE3 (Hansen et al. 2004). Of the
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SLC26 anion exchangers, SLC26A6 appears on the apical membrane of the non-ciliated
cells  of  the  human ED (Kujala  et  al.  2007).  In  addition,  expression  of SLC26A3 mRNA
emerges in the mouse ED (Lee et al. 2001). The role of these SLC26 family members in
the ED remains, however, undetermined.
Spermatozoa reach their competence in motility during their passage through the ducts
of  the  epididymis,  in  which  reabsorption  occurs  at  a  much  lower  rate  than  in  the  ED.
Whereas Na+-dependent fluid reabsorption in the epididymis is low, anion secretion is
crucial for the balance of the luminal microenvironment. Both NHE3 and CFTR are
expressed in the apical membrane of the epididymal ducts in rodents. The data on the
precise cell types involved are inconsistent (Bagnis et al. 2001, Leung et al. 2001b). Of the
SLC26 family members, SLC26A6 appears on the apical mitochondria-rich cells
(AMRCs) of the epididymis (Palacios et al. 1991) and SLC26A7 on the basolateral
membrane of the basal cells (Kujala et al. 2007), suggesting their role in the epididymal
anion exchange.
An essential feature in both the ED and epididymal transport is sperm acidification by
proton pumping through the apical vacuolar proton-transporting ATPase (V-ATPase).
This acts to promote an acidic microenvironment for the storage of sperm in the cauda
epididymis and vas deferens. The acidic luminal environment keeps spermatozoa immotile
during storage, and allows motility only after neutralization by the alkaline fluids from the
prostate and seminal vesicles (Breton et al. 1996, Herak-Kramberger et al. 2001). HCO3-
ions  alone  are  able  to  activate  sperm  motility  during  ejaculation  (Okamura  et  al.  1985).
Furthermore, CFTR-mediated HCO3- secretion from the endometrial epithelium is
required for sperm capacitation and egg-fertilizing ability (Wang et al. 2003).
Figure 6 Cross-section of a seminiferous tubule from a patient with CLD (left), and
arrangement of the tubules of the testis and epididymis (right).
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4.2 Genetic causes of male infertility in humans
4.2.1 Chromosomal abnormalities
Primary failure of spermatogenesis, resulting in azoospermia (no sperm in the semen) or
oligozoospermia (sperm count <5 million/ml), is often caused by numerical or structural
chromosomal abnormalities (Gianotten et al. 2004). In addition to various karyotype
changes, these defects include Y-chromosomal deletions. Both partial and complete
deletions in the azoospermia factor (AZF) locus of the Y chromosome result in a failure of
spermatogenesis and in various abnormalities of testicular histology (Pryor et al. 1997).
The most common consequence of Y-chromosomal deletions is azoospermia (Tiepolo and
Zuffardi 1976). Among Finnish azoospermic/oligozoospermic men, their 9% incidence of
Y deletions equals figures from other countries (Aho et al. 2001).
4.2.2 Cystic fibrosis and CBAVD
A hallmark of cystic fibrosis (CF) is congenital bilateral absence of the vas deferens
(CBAVD) (Kaplan et al. 1968). In addition, CF involves various anomalies of the seminal
vesicles (Olson and Weaver 1969). Despite the obstructive azoospermia and infertility in
CF, spermatogenesis is active, but spermatozoa morphology may be abnormal (Denning et
al. 1968). CFTR may thus play a primary role in anion secretion not only in the
epididymis and vas deferens (Tizzano et al. 1994), the sites of the anatomical defect, but
also in the seminiferous epithelium (Gong et al. 2001).
CBAVD,  together  with  anomalies  of  the  seminal  vesicles,  emerges  also  as  a  distinct
entity  in  otherwise  healthy  men (Meschede  et  al.  1997).  In  these  subjects  with  CBAVD
and infertility only, mutations in the CFTR gene are common. As the frequency of at least
one mutated CFTR allele totals as much as 70 to 80% (Anguiano et al. 1992), CBAVD
can  be  considered  a  mild  reproductive  form  of  CF.  Many  of  the  patients  with  CBAVD
only are heterozygous for CFTR mutations, or even homozygous for two mild mutations
(De Braekeleer and Ferec 1996). The most common cause of CBAVD is, however,
heterozygosity for both one CFTR mutation and one 5T allele in the intron-8 polymorphic
polythymidine tract (IVS8-T; alleles 5T, 7T, or 9T) of CFTR (Chillon et al. 1995). The 5T
allele in the intron 8/exon 9 splice-acceptor site results in alternative splicing of mRNA,
and in skipping of exon 9 (Chu et al. 1993). As a low number of normal CFTR transcripts
leads to defective activity of the CFTR channel, the 5T allele is regarded as a mild
mutation. When present in trans with another CFTR mutation, 5T can result in male
infertility, non-classic CF, or even in the normal phenotype (Chillon et al. 1995, Meschede
et al. 1997). The underlying cause of various 5T-associated phenotypes seems to be the
number of the adjacent TG repeats, ranging from 10 to 13. Long TG repeats together with
the 5T allele are more likely to result in aberrant CFTR splicing and in increased disease
penetrance (Groman et al. 2004).
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The presence of only one 5T allele or CFTR mutation in some males with CBAVD, or
even in those with idiopathic oligozoospermia, suggests that some other genetic defects
may contribute (van der Ven et al. 1996, Meschede et al. 1997, Larriba et al. 1998, Schulz
et al. 2006). As the first evidence of compound genetic defects, heterozygosity for
Y-chromosomal deletions and CFTR mutations may lead to idiopathic male infertility
(Karpman et al. 2007).
In Finland, CF is a very rare entity with an incidence of 1:25 000, being one of the
lowest among Caucasian populations (Kere et al. 1994). The Finnish mutation spectrum of
CFTR is unique, as well (Kinnunen et al. 2005). Among Finns, the role of CFTR
mutations or the 5T allele in male infertility remains unclarified.
4.2.3 Other causes
Mutations or expanded CAG repeats in the androgen receptor (AR) gene are associated
with  male  infertility  (Gianotten  et  al.  2004).  Among  Finns,  some  rare AR variants  may
account for male infertility, whereas CAG repeats seem to be uncommon (Lund et al.
2003a, Lund et al. 2003b). In addition to AR, the estrogenic pathway and especially
variants in the estrogen receptor ? (ER?) gene may play a role in male infertility (Galan et
al. 2005). As for other candidate genes for male infertility, functional evidence is limited
or lacking (Gianotten et al. 2004).
4.3 Genetic causes of male infertility in mice
4.3.1 Estrogen receptor ? and NHE3
In mice, an essential gene for male fertility is estrogen receptor ? (ER?). Estrogen
promotes, through ER?, the NHE3-mediated fluid reabsorption in the ED of the testis
(Zhou et al. 2001, Hess 2003). Targeted disruption of ER? results in downregulation of
NHE3, and inhibition of the Na+-dependent fluid reabsorption. The resulting accumulation
of  fluid  in  the  ED,  dilation  of  the  tubules  of  the  ED,  and  dilution  of  sperm  lead  to
infertility. Moreover, disrupted epithelial cytoarchitecture in the ED causes obstruction
and reflux of the accumulating fluids, inducing testicular atrophy (Hess 2003).
Similar to that seen in ER?-deficient mice, accumulation of fluid into the ED and
infertility emerge also in NHE3 knock-out mice, making NHE3 probably the most critical
protein for fluid reabsorption in the ED (Zhou et al. 2001).
In addition to NHE3, estrogen regulates the mRNA levels of several other transporters
in the mouse ED. Of these, CFTR and SLC26A3 are, unlike NHE3, regulated by estrogen
receptor ? (ER?) (Lee et al. 2001). Interestingly, the reproductive capacity of ER?
knockout mice is totally normal (Ogawa et al. 1999). Similarly, CFTR knock-out mice
exhibit normal reproductive function (Snouwaert et al. 1992), although CFTR mutations
cause male infertility in humans.
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4.3.2 Defective ion transport during spermatogenesis
Defects in ion transport during spermatogenesis seem to play a role in mouse male
infertility. Targeted disruption of the Cl-/HCO3- exchanger AE2, which is expressed in
developing spermatozoa, causes infertility by interrupting spermatogenesis (Medina et al.
2003). Similarly, disruption of the Na+-K+-2Cl- cotransporter (NKCC1), which shows a
wide pattern of expression in the seminiferous epithelium, causes defective
spermatogenesis (Pace et al. 2000). In addition, defects in sperm volume regulation are
associated with poor motility of sperm and mouse male infertility (Yeung et al. 2000).
5 Chloride transport in the kidney cortical collecting duct
5.1 Cell types and transporters
The cortical collecting duct (CCD) of the kidney exhibits several mechanisms for Cl-
transport. These include voltage-driven paracellular absorption, the driving force of which
is Na+ reabsorption through the aldosterone-sensitive epithelial Na+ channel ENaC of the
principal cells. The majority of the Cl- transport  is  transcellular,  however,  occurring
through the intercalated cells of CCD (Schuster and Stokes 1987).
Intercalated cells are either H+-secreting type A or HCO3--secreting type B cells.  The
third type is non-A non-B cells (Kim et al. 1999). Between the intercalated cells are
located principal cells which reabsorb Na+ through  apical  ENaC,  and  luminal  water
through the apical water channel aquaporin 2 (AQP2) (Figure 7) (Nielsen et al. 1993).
In the type A intercalated cells, apical V-ATPase excretes protons into the urine
(Wagner et al. 2004). At the same time, HCO3- ions are transported into the blood through
a basolateral Cl-/HCO3- exchanger called the anion exchanger 1 (AE1) (Kim et al. 1999).
In the type B intercalated cells, transporter processes are opposed by an apical Cl-/HCO3-
exchanger SLC26A4, excreting HCO3- into the urine (Royaux et al. 2001), and basolateral
V-ATPase, transporting H+ into the blood (Kim et al. 1999). The transport processess of
the non-A non-B intercalated cells remain undetermined. In these cells, V-ATPase is
present  on  the  basolateral  membrane,  and  both  V-ATPase  and  SLC26A4 are  present  on
the apical membrane (Figure 7) (Kim et al. 1999).
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Figure 7 Acid-base exchange in the kidney cortical collecting duct.
5.2 Regulation of chloride transport
As Cl- is part of the transport processes in both the apical and basolateral membrane of the
intercalated cells, Cl- is needed for both the acidification and alkalinization of the urine,
meaning that Cl- transport in the CCD is essential for the final regulation of acid-base
balance (Schuster and Stokes 1987).
The apical Cl-/HCO3- exchanger SLC26A4 is regulated in response to changes in Cl-
balance. Cl- depletion specifically upregulates SLC26A4, increasing both the reabsorption
of Cl- and excretion of HCO3- (Quentin et al. 2004, Vallet et al. 2006). Thus, upregulation
of SLC26A4 may attenuate the development of metabolic alkalosis during salt restriction.
Accordingly, during salt depletion, SLC26A4-deficient  mice  are  more  prone  to  the
development of metabolic alkalosis (Royaux et al. 2001).
In addition to the regulation of acid-base status, SLC26A4 is essential for the
maintenance of blood pressure and for fluid and electrolyte balance. Aldosterone
specifically upregulates SLC26A4 on the type B intercalated cells of the CCD, resulting in
increased NaCl uptake, volume expansion, and hypertension (Royaux et al. 2001). To
support the central role of SLC26A4 in the regulation of blood pressure, SLC26A4-
deficient mice fail to undergo an increase in blood pressure in response to aldosterone
analogues (Verlander et al. 2003).
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Aims of the study
The aims of this study were
1) to characterize the long-term outcome of CLD in a unique sample of Finnish
patients
2) to search for novel manifestations of CLD, based on extraintestinal expression of
the SLC26A3 gene
3) to study the effectiveness of oral butyrate in resolving the diarrheal symptoms of
CLD
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Materials and methods
1 Study subjects and samples
1.1 Patients with CLD (I, II, IV, V)
By connecting genetic studies (Hoglund et al. 1996b) and collaboration with the pediatric
gastroenterologists  of  the  Finnish  university  hospitals,  we  ascertained  that  altogether  46
patients  aged  over  seven  years  had  had  a  diagnosis  of  CLD.  Of  these,  one  had  died
accidentally, two had been lost to follow-up, and seven refused to participate. The
remaining 36 patients (ages 10-38; median 21), comprising 20 females (56%) and 16
males (44%), were enrolled. They belonged to 27 families, of which four had two affected,
and three had three affected children. All patients presented a typical clinical picture of
CLD, with a high concentration of fecal Cl- (>90 mmol/l) (Holmberg 1986). Mutational
analysis of the SLC26A3 gene was available for 31 (86%) patients, and showed a
homozygous V317del genotype (n=30) or a heterozygous V317del/344delT genotype
(n=1).
For  the  first  part  of  the  study  (I),  the  patients  were  divided  into  subgroups  based  on
their decade of birth: 1960s (n=8; ages 31-38), 1970s (n=7; ages 22-30), and 1980s (n=21;
ages 10-21). The 1980s group comprised three patients actually born in 1990 or 1991.
In the second part of the study (II), the fertility potential was assessed in eight Finnish
males (ages 18-38; median 29.5) with CLD. All of them had participated in the first part
of the study, as well. All but one of the men had an established genetic background of
CLD with the homozygous V317del genotype.
In the fourth part of the study (IV), the influence of butyrate was under study in a
series of five patients with CLD. Of these, three belonged to the original study population
of 36 patients (I), but the two youngest were enrolled as new participants in the butyrate
trial. Peripheral blood DNA samples were available from all these patients and were later
sequenced for all SLC26A3 exons (patient 1) and analyzed for CFTR mutations.
In the fifth part of the study (V), renal outcome was assessed among the original study
sample of 36 patients (I). Data on one male patient (homozygous V317del genotype) with
renal transplantation due to end-stage renal disease (ESRD) were assessed as a separate
case (case 1). Material for another case (case 2) came from a deceased Swedish girl
(homozygous H124L genotype) with a CLD-associated ESRD and renal transplantation.
36
1.2 Tissue samples (II, III, V)
Testis  biopsy  specimens  (n=2),  one  containing  also  the  ED  region  of  the  testis,  were
obtained during operations for large spermatoceles from two males  (aged 29 and 30) with
the homozygous V317del genotype for CLD (II). Specimens were sectioned, fixed with
formaldehyde, and embedded in paraffin. Sections with a thickness of ~5 µm were stained
with hematoxylin and eosin for histological analyses (II) or underwent
immunohistochemical  procedures  for  expression  studies  (III).  Control  samples  were
archival specimens from adult men (aged 22-65) obtained from the Department of
Pathology, HUSLAB, Helsinki University Central Hospital. The specimens involving both
testis  and  epididymis  (n=11)  were  from  patients  orchiectomized  for  seminoma,  cysta
dermoides, cystadenoma, carcinoma embryonale, or teratoma. The seminal vesicles (n=9)
and prostates (n=4) were from patients with radical prostatectomies due to focal prostatic
carcinoma. Original reports of the pathologists were reviewed before use of histologically
healthy samples with normal spermatogenesis (III). Stages of spermatogenesis were
assessed (Holstein et al. 2003), and specimens of the ED and epididymis were divided
histologically into initial and terminal zones according to their anatomical positions on the
slides and based on their cell morphology and location (Robaire and Hinton 2002). In the
seminal vesicles and prostates, higher glandular and lower unreactive ductal epithelium
were histologically recognized (Gartner and Hiatt 1997).
One kidney biopsy specimen from case 1, taken before transplantation at the age of 19,
was available for immunohistochemistry (V). In addition, kidney biopsy slides after
transplantation, stained with hematoxylin and eosin or von Kossa stain for calcium
deposits, were available from both case 1 and case 2. Archival human kidney samples
came from the Department of Pathology, HUSLAB, Helsinki University Central Hospital.
The nephrectomy specimens (n=5) were from patients with focal nephroblastoma or renal
cell carcinoma, and kidney biopsy samples (n=5) from healthy kidney donors.
Histologically healthy areas of the samples were used, after review of the original reports
of the pathologists (V).
Frozen cortical samples from normal human kidneys (n=3) not needed for
transplantation use and cortical samples from patients nephrectomized for congenital
nephrotic syndrome (CNF) (n=9) were the gift of a collaborator (H. Jalanko) for reverse
transcriptase polymerase chain reaction (RT-PCR) (V). Non-glomerular cortical portions
of healthy human kidneys (n=4) not needed for transplantation use were obtained
correspondingly for western blotting.
Control complementary DNA (cDNA) samples (V) were from human multiple tissue
cDNA panels (kidney and skeletal muscle: Clontech, Mountain View, CA, USA), and
from Gene Pool cDNA (colon and kidney: Invitrogen, Carlsbad, CA, USA).
Commercial human tissue lysates from kidney, colon (positive control), and liver
(negative control) were used in western blotting (V) (Zyagen Laboratories, San Diego,
CA, USA).
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2 Methods
2.1 Clinical analysis of long-term outcome (I, V)
Participants’ medical data were reviewed from birth. Clinical studies were performed at
the pediatric units of the university hospitals in Helsinki (patients, n=17), Oulu (n=12), or
Kuopio  (n=7).  From  current  heights  and  weights,  height  standard  deviation  (SD)  scores
were compared with the Finnish reference values (Sorva et al. 1990). In adults, body mass
index (BMI) 19 to 25 kg/m2 was regarded as normal. In children, BMI cut-off points for
overweight were based on age and sex (Lindgren et al. 1995).
Laboratory studies involved 24-h blood pressure recording, chest X-ray,
electrocardiography (ECG), and renal ultrasound with an assessment of measured renal
lengths as SD scores (Rosenbaum et al. 1984, Miletic et al. 1998). Laboratory tests were
total blood count, erythrocyte sedimentation rate, venous blood gas analysis (Astrup),
serum  K+, Na+, Cl-, Ca2+, Mg2+, Pi, uric acid, alkaline phosphatase, creatinine, urea
nitrogen, osmolality, plasma renin activity, and aldosterone. Standardization of the two
different radioimmunoassay techniques for aldosterone measurements (DiaSorin, Inc.,
Stillwater, MN, USA; DPC, Los Angeles, CA, USA) was performed in the laboratory of
HUSLAB, Helsinki University Central Hospital. Concentrations of fecal K+, Na+, and Cl-
were measured from single specimens. Urine analyses (24-h collection) were for pH and
for concentrations of K+, Na+, Cl-, Ca2+, Mg2+,  Pi,  and  protein.  Chrome  51
ethylenediaminetetraacetic acid (51Cr-EDTA)  clearances  allowed  estimation  of  the
glomerular filtration rates (GFR). Quantitative sweat tests with stimulation by pilocarpine
iontophoresis furnished a record of sweat Cl- excretion. The most of the laboratory data
was assessed in study I, but investigations for renal function were reported separately (V).
The oral and dental examinations involved 28 patients. The decayed, missing, filled
surfaces of teeth (DMFS) index allowed assessment of dental health, and the community
periodontal index of treatment needs (CPITN) index of periodontal health. The quality of
the dental enamel was visually evaluated, followed by panoramic radiographs of the
dentition.
The patients completed a questionnaire including details of therapy, compliance,
dietary factors, general state of health (five-step scale: excellent, good, satisfactory,
relatively poor, poor), marital status, children, education, and employment.
Numerical data were analyzed by the Statistical Package for Social Sciences (SPSS)
software versions 10.0 or 15.0. Significance was set at p<0.05. Fisher’s exact test
compared differences in mortality between groups (I). Differences between laboratory
data were determined two groups at a time by the Mann-Whitney U test  (I),  a  test  also
used to compare relative renal lengths with patients’ relative heights (V). Spearman’s
correlation coefficients (rs) were used to study relations between measurements of renal
function and other laboratory data (V).
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2.2 Clinical analysis of male fertility (II)
Eight males with CLD underwent physical examinations with venous blood samples taken
to measure levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH),
testosterone, and inhibin B. Single semen samples were provided by masturbation (after
an abstinence of 3-7 days). Sperm analyses were performed according to the WHO
guidelines (Menkveld et al. 2001). Sperm motility classes were: A with rapid forward
progressive spermatozoa, B with slowly forward progressive, C with non-progressive, and
D with immotile spermatozoa.  Normal values for sperm motility were ?50% with forward
progressive (categories A and B) or ?25% with rapid progressive (category A)
spermatozoa within 60 minutes of ejaculation. For sperm morphology, the reference for
normal spermatozoa of ?30% was used.
Patency  of  the  vas  deferens  was  assured  by  measurement  of  levels  of  neutral  alpha-
glucosidase (Lund University, Sweden). Secretory potential of the seminal vesicles was
studied by measurement of seminal plasma fructose, and of the prostate by zinc
measurement (Lund University). In addition, pH values and levels of seminal plasma K+,
Na+,  and Cl- were assessed. To obtain reference values, seminal plasma pH, electrolytes,
and fructose were measured in eight healthy males with pregnancy-proven fertility.
2.3 Butyrate trial (IV)
During the entire study, the five study patients received their salt substitution, followed a
normal  diet,  and  completed  a  daily  diary  to  record  their  dosage  of  salt  substitution  and
butyrate, possible adverse events, and diarrheal symptoms including number and
consistency of stools (watery, semiformed, formed), soiling, abdominal distention, and
stomach cramps.
Initially, these patients kept their diaries for five days during their normal salt
substitution therapy, providing baseline data on their diarrheal symptoms. Thereafter, they
received two daily doses of capsules with calcium and magnesium butyrate salts (Butyric
acid complex; BioCare, UK) at a butyrate dose of 100 mg/kg/day for 10 days. After
clinical evaluation, blood, urine, and fecal samples were obtained at the butyrate trial
entry, immediately after the 10-day butyrate trial, and 20 days after halting the butyrate.
Laboratory tests comprised total blood count, venous blood gas analysis, plasma
concentrations for ammonium ion, unconjugated and conjugated bilirubin, and parathyroid
hormone, plasma renin activity, serum K+, Na+, Cl-, Ca2+, Mg2+, Pi, osmolality, creatinine,
aldosterone, urate, urea nitrogen, protein, albumin, glucose, alanine transaminase,
aspartate transaminase, alkaline phosphatase, and gamma glutamyl transferase. Fecal K+,
Na+,  and  Cl-, concentrations of the fecal inflammatory markers ?1-antitrypsin and
calprotectin, and concentrations of urine K+, Na+, Cl-, Ca2+, Mg2+, and Pi were measured
from single specimens.
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2.4 Antibodies (III, V)
Antiserum for SLC26A3, raised in rabbits against the synthetic peptide
FNPSQEKDGKIDFT, corresponding to amino acids 732-745 of the published cDNA
sequence, had been purchased from Research Genetics (Huntsville, AL, USA) (Haila et al.
2000). This antiserum was diluted to 1:350, and preimmune serum served as a negative
control in consecutive sections (III, V).
Mouse monoclonal antibody against a synthetic peptide from the N-terminus of the
human CFTR protein (CFTR Ab-2, MM13-4; NeoMarkers, Fremont, CA, USA) was used
at 1-2 ?g/ml, and normal mouse serum IgG fraction (NMIgG; Labvision, Fremont, CA,
USA) served as a negative control in consecutive sections (III).
Rabbit polyclonal, affinity-purified antibody for the 22 C-terminal amino acids of the
rat NHE3 (NHE-31A; Alpha Diagnostics International, San Antonio, TX, USA) was used
at 1 ?g/ml, and normal rabbit serum IgG fraction (NRIgG; DAKO, Hamburg, Germany)
as a negative control in consecutive sections (III).
The following affinity-purified polyclonal antibodies were used in
immunohistochemistry  on  kidney  samples  (V):  rabbit  anti-human  vacuolar  type
H+-ATPase (V-ATPase) B1/2 (V-ATPase-B, sc-20943; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) (Kujala et al. 2005), rabbit anti-rat aquaporin 2 (AQP2) (AQP21-A;
Alpha Diagnostics International, San Antonio, TX, USA), and mouse anti-human Pendrin
(alias SLC26A4) (MBL, Woburn, MA, USA) (Royaux et al. 2001). NRIgG and NMIgG
served as negative controls.
2.5 Immunohistochemistry (III, V)
Formalin-fixed and paraffin-embedded specimens were cut into ~5-?m sections on a
microtome and mounted on glass slides. Antigens were retrieved by boiling in a 10-mM
citrate buffer (pH 6.0) for 10 min (III, NHE3), 15 min (III, SLC26A3), or 20 min (III,
CFTR; V). Immunohistochemistry was performed with EnVision kits (DakoCytomation,
Carpinteria, CA, USA): EnVision+ System K4010 (SLC26A3, AQP2, and NHE3),
EnVision+ System K4006 (SLC26A4 and CFTR), and EnVision Doublestain System
K1395 (SLC26A3 and V-ATPase) according to manufacturer’s instructions. The sections
were incubated with the primary antibodies SLC26A3 (1:350), SLC26A4 (0.2 ?g/ml),
CFTR (1-2 ?g/ml), NHE3 (1 ?g/ml), AQP2 (1 µg/ml) for 60 min, or at 4°C overnight (III,
SLC26A3). The slides were stained with diaminobenzidine (DAB) for 8 min, and
counterstained with Mayer’s hematoxylin (Merck, Darmstadt, Germany). Finally, the
slides were dehydrated, and cover slips were placed on top.
In doublestained slides, DAB staining was followed by a blocking agent provided by
the kit supplier, and incubation with the V-ATPase antibody (1:1000) for 30 min at room
temperature. The slides were stained with Fast Red for 4 min, counterstained with
hematoxylin, treated with 0.037 mmol/l ammonia water, rinsed, and covered.
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2.6 CFTR mutation analysis (IV)
To clarify the potential contributors to the diverse butyrate responses, we searched for
possible butyrate-responsive variants of the CFTR gene (Kerem 2006). CFTR fragments
were prepared by a multiplex amplification kit (Amplification CFTR; Innogenetics, Gent,
Belgium) from DNA samples extracted from patients’ peripheral blood samples.
INNO-LiPA CFTR17+Tn and CFTR19 test strips (Innogenetics) were used. These assays
recognize IVS8-T polymorphism on intron 8, and the following 36 mutations: 621+1G>T,
3849+10kbC>T, 2183AA>G, 394delTT, 2789+5G>A, R1162X, 3659delC, R117H,
R334W, R347P, G85E, 1078delT, A455E, 2143delT, E60X, 2184delA, 711+5G>A,
F508del, G542X, N1303K, W1282X, G551D, 1717-1G>A, R553X, CFTRdel2,3(21kb),
1507del, 711+1G>T, 3272-26A>G, 3905insT, R560T, 1898+1G>A, S1251N, I148T,
3199del6, 3120+1G>A, and Q552X. These CFTR assays  cover,  in  total,  87%  of  the
Finnish CFTR mutations (Kinnunen et al. 2005).
2.7 Sequencing (IV)
In the butyrate-responsive subject (patient 1), exons (n=21) and exon/intron boundaries of
the SLC26A3 gene were amplified by PCR with intronic primers (Haila et al. 1998). PCR
amplifications (10 µl/reaction) involved 20 ng of genomic DNA, 200 µM of each
nucleotide, 2 mM MgCl2, 9 pmol of each primer, and 0.25U AmpliTaq Gold DNA
polymerase  with  1X  buffer  (Applied  Biosystems,  Foster  City,  CA,  USA).  The  PCR
protocol involved 1 cycle of 10 min at 94°C, 30 cycles of  94°C for 45 seconds, 57°C for
45 seconds, 72°C for 45 seconds, and 1 cycle of 72°C for 10 min.
For all subjects in the butyrate trial, the polymorphic IVS8-T locus of intron 8 of the
CFTR gene and the number of adjacent TG repeats were analyzed with intronic primers:
5’-TAATGGATCATGGGCCATGT-3’ and 3’-ACAGTGTTGAATGTGGTGCA-5’
(Zielenski et al. 1991). PCR amplifications were performed as described for SLC26A3,
except for the annealing temperature of 54°C for CFTR.
The fragments were characterized by direct sequencing (ABI 3730xl DNA Analyzer;
Applied Biosystems) in one direction (SLC26A3)  or  two  directions  (CFTR)  with  the
BigDye Terminator 3.1 chemistry (Applied Biosystems). SeqScape Software 2.5 (Applied
Biosystems) was used for the analysis of SLC26A3 sequences with the complete human
SLC26A3 DNA (GenBank accession NM_000111) as a reference sequence. Sequences of
the polymorphic IVS8-T locus of CFTR were assessed manually.
2.8 RT-PCR (V)
Frozen cortical samples from human kidney were homogenized and used for total RNA
extraction  with  the  RNeasy  Mini  Kit  (Qiagen,  Valencia,  CA,  USA),  after  which  cDNA
was synthesized with the SuperScript III First Strand Synthesis System (Invitrogen,
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Carlsbad, CA, USA) using random hexamers. The quality of cDNA was ensured by PCR
for a housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Applied
Biosystems, Foster City, CA, USA).
SLC26A3 primers, 5’-AAACACCGTAGGAGATTGCTTC-3’ and
3’-ATCAGCATTCCCTTTAAGTTTCC-5’, were designed into exonic junctions to avoid
amplification of genomic DNA. PCR assays were prepared in 25-µl volumes involving
4 µl cDNA template, 200 µM of each nucleotide, 0.4 µM of both primers, 4% dimethyl
sulfoxide, 1 x Phusion GC Buffer, and 0.02 U/µl Phusion High-Fidelity DNA polymerase
(Finnzymes Oy, Espoo, Finland). The touch-down PCR protocol was: 98?C for 30 s, 35
cycles of 98?C for 10 s, 60?C minus 0.5?C per cycle for 30 s, and 72?C for 1 min 30 s,
without final extension. PCR products of 348 bp, corresponding to nucleotides 1010-1357
of the published SLC26A3 cDNA, were subjected to electrophoresis on a 2% agarose gel.
The products were purified with ExoSAP-IT (USB, Cleveland, Ohio, USA) and
sequenced in both directions (ABI 3730xl DNA Analyzer; Applied Biosystems, Foster
City, CA, USA).
2.9 Western blotting (V)
Kidney samples (n=7) were homogenized in Laemmli sample buffer with 5%
?-mercaptoethanol. Electrophoresis was performed with 30 ?g of each sample in a 9%
polyacrylamide gel. The proteins were transferred onto a Hybond-C extra nitrocellulose
membrane (Amersham Pharmacia Biotech, Bucks, UK) by standard protocols. After
blocking with 5% non-fat dry milk in Tris-buffered saline with Tween 20 (TBST), pH 7.6,
the membranes were incubated with the SLC26A3 antiserum (1:350), or with the
preimmune serum (1:350), followed by incubation with peroxidase-conjugated goat anti-
rabbit IgG (1:2000) (Roche Diagnostics, Mannheim, Germany). Chemiluminescence
served for visualization of the protein bands (GE Healthcare, Princeton, NJ, USA).
3 Ethics
The study protocols involving all parts of the study were approved by the Ethics
Committee of the Hospital for Children and Adolescents, University of Helsinki. Informed
consent was obtained from each patient or, when appropriate, from parents.
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Results
1 Long-term outcome in CLD
1.1 Survival, diagnosis, growth, and general state of health
After 1972, no CLD-associated deaths occurred (I, Figure 1). Mean age of patients at
diagnosis of CLD was 2.7 months (range, 0-59) with a tendency towards earlier diagnoses
during the most recent decades (I, Figure 2). Most patients (97%) had attended annual
follow-up visits at the pediatric units until the age of 20. Later in life, ten patients (28%)
made irregular follow-up visits for CLD.
The  patients  showed  normal  growth  with  a  mean  relative  height  of  +0.07  SD,  mean
expected height being +0.17 SD. Among the oldest patients, early growth retardation was
evident, but normalization of mean growth was observable by age three years (I, Figure 3).
At the time of evaluation, ten patients (28%) were slightly overweight, and five (14%)
underweight. An 18-year-old female with unspecified colitis and severe malnutrition had a
BMI of only 11.7 kg/m2.
In  addition  to  CLD,  a  variety  of  other  diseases  emerged  in  this  series  of  patients  (I,
Table 3), but in the questionnaires, 31% regarded their health as excellent, and 61% as
good. Two patients defined their health as satisfactory, and only one as poor.
Most patients (89%) had had standard schooling; indications for some special
education at comprehensive school were moderate learning difficulties (n=3) and mild
sensorineural hearing loss (n=1).
1.2 Diarrhea and salt substitution
All patients reported watery diarrhea from two to seven (mean 3.6) times per day. Most
patients had adjusted to their diarrhea, experiencing only minimal social disadvantages.
None of the patients had marked abdominal distention, but soiling was a common finding;
53% of the patients aged under 20, and 32% over 20 reported occasional soiling during the
night-time or during physical exertion. Three young adults (8%) with frequent soiling
problems found the diarrheal symptoms of CLD disturbing.
To temporarily reduce the diarrhea, four patients had used short courses of
cholestyramine (dose 2 g x 2/day), resulting in a moderate reduction in diarrhea for two to
four weeks. In addition, 14% of the patients reported that dietary bulk reduced their
diarrheal symptoms.
According to the past clinical guidelines, patients born in the 1960s had received salt
substitution with KCl during their first four to ten years of life (Holmberg 1986), whereas
the younger patients were already receiving increasing doses of NaCl and KCl from the
time  of  their  diagnoses  (I,  Table  1).  Current  daily  doses  of  Cl- ranged from 0.9 to 5.3
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(mean 2.8) mmol/kg per day. The substitution was taken as 2 to 5 doses per day as a
ready-made solution (26 patients) of NaCl 18 g/l (308 mmol/l) and KCl 19 g/l
(255 mmol/l), or as one dose at a time diluted in a glass of water (10 patients). Substitution
therapy was well tolerated, but after ingestion of the salts, two patients (6%) experienced
occasional stomach cramps.
Regular salt substitution was the rule for most patients (81%), but six patients had
frequent breaks (>2 weeks), often after beginning to take responsibility for their own
therapy (mean age, 12.9 years).
The youngest patients (group 1980s) achieved the most nearly optimal electrolyte and
acid-base balance, with no hypokalemia, hypochloremia, or alkalosis, and adequate
secretion of Cl- into the urine in all subjects (I, Table 2). Of other laboratory tests, elevated
erythrocyte sedimentation rates (>30 mm/h in four patients) were evident in 10 patients
(28%). Serum creatinine, urea nitrogen, and blood pressure were normal in all but the
single patient with a renal transplant, who showed a creatinine concentration of
455 ?mol/l, urea nitrogen of 45 mmol/l, and blood pressure of 124/89 mm Hg. Chest X-
rays and ECGs showed no abnormalities.
1.3 Major extraintestinal findings
1.3.1 Intestinal inflammation
Solitary cases of intestinal inflammation emerged. A 37-year-old woman had a diagnosis
of CLD at 2.5 months and Crohn’s disease at 18 years. In addition, a 18-year-old woman
exhibited frequent watery diarrhea (6-7 times/day), soiling problems, enuresis, and weight
deficit (BMI 11.7 kg/m2) requiring intermittent parenteral nutrition. Despite extensive
investigations, no other disease than CLD and unspecified colitis had been diagnosed in
this patient with a homozygous V317del genotype for CLD. In her sister, a totally
uneventful course of CLD occurred.
1.3.2 Renal impairment
In our series, 10 patients (28%) fullfilled the criteria for chronic kidney disease (CKD) (V,
Table 1). In both the one Finnish patient with CLD and ESRD (V, case 1) and in the
Swedish patient with CLD, agenesis of the left  kidney, and ESRD (V, case 2),  the most
striking renal feature was abundant nephrocalcinosis. It appeared in the patients’ own
kidneys,  and  later,  in  their  transplants  as  well  (V,  Figure  1).  Ultrasonic  signs  of
nephrocalcinosis  were  also  common in  other  patients,  although the  decline  in  their  GFR
levels was only mild (V, Table 1).
Electrolytes, acid-base and fluid balance, and calcium-phosphate balance showed
slight abnormalities only in individual patients, but urine was alkaline (pH>7) in 13 (37%)
(V, Table 2).
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Relative renal lengths, showing a positive correlation with GFR values, fell
significantly below the patients’ relative heights (V, Figure 2).
The subgroup of patients with lower GFR levels (<110 ml/min/1.73m2) had
significantly lower excretion of urinary NaCl, and lower blood pressure, but higher
erythrocyte sedimentation rates, as a non-specific measure of inflammation (V,
Figure 3A-D). Regarding urinary measurements, a positive correlation appeared between
urinary  excretion  of  Ca2+ and NaCl (V, Figure 3 E-F). Inadequate urinary Cl- excretion
(<83 mmol/day) was associated with lower Na+ excretion and with higher urinary pH, but
with no differences in venous blood HCO3- or aldosterone (V, Figure 4).
1.3.3 Hyperuricemia
The patient  with  a  history  of  ESRD and renal  transplantation  had  gouty  arthritis  and  an
elevated serum urate level of 548 ?mol/l despite allopurinol medication. Three additional
patients in the 1960s group were hyperuricemic (364, 484, and 576 ?mol/l) without gout.
In  renal  ultrasound,  two  had  calcifications.  The  mean  concentration  of  serum  urate  was
significantly lower in the 1980s group when compared with the 1960s (p<0.05) and the
1970s group (p<0.05).
1.3.4 Elevated sweat chloride
Mean sweat Cl- concentration was 36 (range, 8-70) mmol/l; 64% had a concentration
below 40, 24% between 40 and 60, and 12% above 60 mmol/l. For screening cystic
fibrosis with the sweat test, a concentration <40 mmol/l is regarded as negative, and
>60 mmol/l as consistent with the disease (LeGrys 1996).
1.3.5 Inguinal hernias, spermatoceles, and male subfertility
Of 16 men, four (25%) had undergone surgery for inguinal hernia, three of them in
infancy. Additionally, one adult had undergone surgery for spermatocele. As a novel
finding, bilateral spermatoceles appeared in two adults.
Of the four men who lived in a permanent relationship with a woman, three had
experienced infertility. None had naturally conceived children, but one had fathered a
child through in vitro fertilization (IVF). By contrast, seven women with CLD had a total
of 14 healthy children after uneventful pregnancies.
1.3.6 Infections
All but one patient had been hospitalized for acute gastroenteritis (AGE). Such
hospitalization was most common in early childhood with a mean 3.6 (SD=2.7) episodes
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during the first five years of life. Later in life, the incidence was 2.1 (SD=2.6)
hospitalizations between ages six and ten, and 1.5 (SD=2.0) between 11 and 20. In
adulthood, only four patients had been hospitalized due to AGE. Five patients (14%) had
experienced at least one AGE with a dehydration-associated faint or convulsion. Of these,
the most severe hypokalemic (K+ 2.7 mmol/l) episode had resulted in an out-patient
resuscitation.
Urinary tract infections (UTIs) (range, 1-16 per patient) were documented in 13
patients (36%). The mean number of UTIs per patient during the first 10 years of life was
significantly higher in the 1960s group than for the 1980s (p<0.01). Occasional enuresis
occurred in 33% at school-age, 28% by the age of 11, and 8% by the age of 15.
1.3.7 Teeth
The low mean DMFS index (10.1) and low CPITN figures indicated good dental and oral
health, and good periodontal state. Moderate enamel defects emerged in 43%, minor forms
including opacities in 25%, and faultiness of dental enamel in 32%. Three patients had a
permanent tooth congenitally missing, and a 37-year-old female had a sialolith in her right
submandibular duct.
2 Male subfertility in CLD
All eight men had normal masculinization, testes sizes, and sexual function. Testis biopsy
samples, taken from two patients during the operations for spermatoceles (Tables 3 and 4:
patients 4 and 5), showed normal testicular histology.
Hormonal measurements were normal, but semen analyses revealed a low
concentration of poorly motile spermatozoa with abnormal morphology, indicative for
oligoasthenoteratozoospermia (sperm concentration <20 x 106/ml and motility or normal
forms  or  both  <20%)  in  all  but  one  patient  with  azoospermia  (no  sperm  in  semen)
(Tables 3 and 4: patient 5). Any correlation between age and sperm parameters of the
patients was non-existent.
Concentrations of seminal plasma Cl- (Table 4) were significantly higher in the men
with CLD (mean 66 mmol/l) than in their healthy controls (mean 39 mmol/l) (p<0.001),
whereas concentrations of Na+ and  K+ were equal. An abnormally low pH of seminal
plasma emerged in three patients (Table 4), the difference in mean pH values between
patients (pH=7.1) and pregnancy-proven healthy controls (pH=7.5) remaining
insignificant (p=0.06). The levels of seminal plasma alpha-glucosidase were normal in
CLD, proving the patency of the vas deferens. The levels of seminal plasma fructose in
CLD and controls were equal, reflecting otherwise unaffected vesicular absorptive and
secretory functions. The levels of seminal plasma zinc were normal, as well (unpublished
data), indicating normal secretion of prostatic fluids.
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Table 3 Sperm volume, count, and motility (WHO classification) in eight men with CLD
(modified from II).
Patient Age
(yrs)
Volume
(>2 ml)
Count
(>20x106/ml)
Total count
(>40x106)
Motility A
??25%)
Motility A+B
??50%)
Clinical data
1 18 0.5 38 19 0 29
2 22 2 2.5 5 0 2
3 23 2 17 34 9 42
4 29 3.5 11 38.5 5 31 Spermatocele,
testis biopsy
5 30 3.6 0 0 - - Spermatocele,
azoospermia,
testis biopsy
6 36 4 3 12 0 6 Infertility
7 37 8.5 1.2 10.2 2 52 Infertility,
IVF succesful
8 38 3.3 7.1 23.4 0 12 Spermatocele,
infertility
mean 29 3.4 10.0 17.8 2 24.9
Table 4 Seminal plasma pH, electrolytes (mmol/l), and sperm morphology in eight men
with CLD (modified from II).
Patient Age
(yrs)
pH
(>7.2)
Na+ K+ Cl- Abnormal
morphology (%)
head
(%)
body
(%)
tail
(%)
Clinical data
1 18 7.7 132 25 62 97 97 38 6
2 22 6.7 133 27 59 100 100 65 26
3 23 7.4 159 22 73 99 99 42 6
4 29 6.7 132 21 71 97 97 15 3 Spermatocele,
testis biopsy
5 30 7 124 30 64 - - - - Spermatocele,
azoospermia,
testis biopsy
6 36 - - - - 89 - - - Infertility
7 37 - - - - 93 - - - Infertility,
IVF succesful
8 38 7.2 140 22 64 99 99 57 8 Spermatocele,
infertility
mean 29 7.1 137 25 66 96.3 98.4 43.4 9.8
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3 Expression studies in the human male reproductive tract
3.1 Expression profiles of SLC26A3, CFTR, and NHE3
3.1.1 Seminiferous tubules of the testis
Positive staining for SLC26A3 appeared in the head of the elongating spermatids (Sb-Sc)
of stages III to VI, but not in the fully developed spermatozoa. Immunoreactivity emerged
at the cell periphery, first as a polarized labeling (stage III), secondly as a hood on the
head of the elongating spermatid (stage IV), and finally as a band surrounding the center
of the head of the spermatids (stages V-VI). The staining patterns in the males with CLD
and the controls were equivalent (III, Figure 1).
Labeling of CFTR appeared in the pachytene (stages III-V) and diplotene
spermatocytes (stage VI). The round staining patterns suggested the presence of CFTR on
the cell membrane. In the elongating spermatids (Sb), a cranially polarized staining pattern
(stage III) and a hood-like expression profile (stage IV) of CFTR were identical to those of
SLC26A3. In the later stages of spermatogenesis and in the fully developed spermatozoa,
expression of CFTR was absent, similarly to that seen for SLC26A3. The expression
profiles of the males with CLD and the controls were similar (III, Figure 1).
In the seminiferous epithelium of the testis, expression of NHE3 was absent (data not
shown).
3.1.2 Efferent ducts of the testis
In the initial zone of the ED, apical membranes of the non-ciliated cells showed
immunoreactivity  for  SLC26A3,  CFTR,  and  NHE3,  whereas  the  ciliated  cells  remained
negative. In the terminal zone of the ED, no specific immunostaining for the transporters
was observable.
The ED of the patient with CLD was histologically the proximal type, but showed no
staining for SLC26A3 or CFTR. Instead, the expression of NHE3 in the non-ciliated cells
was present, similar to that seen in control samples (III, Figure 2).
3.1.3 Epididymis
In the epididymides of the control patients, apical expression of SLC26A3 and CFTR
appeared on the luminal side of the apical mitochondria-rich cells (AMRCs) (Palacios et
al. 1991). Other cell types remained negative for the proteins studied (III, Figure 2).
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3.1.4 Seminal vesicle
Both  the  higher  glandular  epithelium  and  lower  unreactive  ductal  epithelium  of  the
seminal vesicles of the controls showed intense apical immunoreactivity for SLC26A3. In
the case of CFTR, no staining appeared in the higher glandular epithelium, but strong
labeling was present, together with SLC26A3, on the luminal side of the lower ductal
epithelium (III, Figure 2).
3.1.5 Prostate
In the controls’ prostate samples, the apical border of the prostatic duct epithelium showed
intense immunoreactivity for CFTR (III, Figure 2), whereas the higher glandular
epithelium remained negative (data not shown). Stainings for SLC26A3 and NHE3
remained negative (data not shown).
4 Clinical trial with oral butyrate in CLD
Butyrate slightly reduced the diarrhea in only one of the five patients (IV, Table 1: patient
1). Other patients reported no effect (patient 2) or even an increased diarrhea (patients
3-5). Accordingly, butyrate reduced the mean number of stools only in patient 1 (from 4.2
to 3.4 stools/day). Butyrate had no effect on soiling episodes or watery consistency of
stools in any of the patients. It was well tolerated, although three patients (patients 3-5)
reported slight abdominal distention and increased bowel movements (unpublished data).
The majority of the laboratory measurements remained unaltered during the butyrate
trial. In all patients, butyrate reduced fecal K+ secretion,  but  urine  and  serum
concentrations of K+ showed more individual variation. In butyrate-responsive patient 1,
the fecal concentration of Cl- showed a substantial 1.4-fold and Na+ a 1.9-fold decrease at
the end of the butyrate trial.  In contrast,  a total  inhibition of urine Cl- excretion, a mean
1.7-fold decrease in urine Na+ excretion, and a tendency toward metabolic alkalosis
appeared in the non-responsive patients (n=4) (IV, Figure 1). Although butyrate reduced
concentrations of serum urea-N (4.2 to 3.6 mmol/l) and urate (198 to 189 µmol/l) in
patient 1, the other patients showed increased mean concentrations of both urea-N (4.4 to
6.1 mmol/l) and urate (255 to 281 µmol/l) (unpublished data).
In butyrate-responsive patient 1, fecal calprotectin and ?1-antirypsin levels showed a
17-fold and 6-fold increase 20 days after stopping butyrate (IV, Figure 1), without signs of
intestinal inflammation. Spontaneous normalization of the values was recorded three
months later.
None  of  the  patients  had CFTR mutations or the 5T allele at the polymorphic locus
IVS8-T of CFTR. In addition, sequencing of the coding regions (n=21) and exon-intron
boundaries of SLC26A3 (Haila et al. 1998) from the DNA sample of butyrate-responsive
patient 1 revealed no other variants than the Finnish founder mutation V317del and the
associated homozygous C307W variant 10 codons upstream (Hoglund et al. 1996b).
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5 Expression of SLC26A3 in the human kidney
Variable levels of expression of renal SLC26A3 mRNA and protein were confirmed with
RT-PCR and western blotting (V, Figure 5). SLC26A3 immunolabeling appeared on the
apical membrane of the distinct cells of the connecting tubule (CNT) and cortical
collecting duct (CCD) (V, Figure 5). As both these ducts have an apical AQP2 transporter
in the principal cells (Nielsen et al. 1993), expression of SLC26A3, occurring in a cell
type different from that of AQP2, was localized in the intercalated cells. Doublestaining
suggested SLC26A3 expression in the cell type with mainly basal and cytoplasmic
staining for V-ATPase as being characteristic of the type B intercalated cells (Kim et al.
1999). The apical signal for SLC26A4 in at least some of the SLC26A3-positive tubules
suggested that the cell type was either the type B or nonA-nonB intercalated cell (Kim et
al. 1999). In the biopsy sample of the patient with CLD, expression of SLC26A3 was
lacking, although staining profiles for other transporters were comparable to those of
controls.
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Discussion
1 Long-term outcome
The first single cases with congenital chloride diarrhea (CLD) were described back in
1945, but not until 20 years later did understanding of the underlying intestinal defect
result in finding a life-saving therapy. Salt substitution with NaCl and KCl is, even today,
the only effective therapy (Holmberg et al. 1977a). After this treatment was introduced in
Finland, with one of the world’s highest CLD incidences, our country has had the world’s
largest series of adolescent and adult patients. This set of patients made identification of
the gene for CLD possible (Hoglund et al. 1996b). In this study, we used this unique
sample of Finnish patients to provide data on the long-term outcome of CLD.
This study series involved 80% of all Finnish patients aged over 7 years (ages 10-38;
median 21). High infant mortality (45%) among patients born in the 1960s, and refusal to
participate (23%) among those born in the 1970s were the most substantial reasons for
non-participation. The final sample of 36 subjects comprised 40%, 54%, and 95% of the
patients born in the 1960s, 1970s, and 1980-1991 (I, Figure 1).
 After the introduction of salt substitution in the late 1960s, only two infants have died
of probable CLD in Finland. CLD cases are usually recognized during fetal development,
based on ultrasonic findings showing polyhydramnios and fluid-filled intestinal loops of a
fetus (Kirkinen and Jouppila 1984). To the best of our knowledge, only two Finnish
patients have lived with undiagnosed CLD for one year or more. One of these is a boy
who received his diagnosis at the age of five—as late as in 1995 (Leskinen 1996).
Diagnostic pitfalls—food allergies in that case—are worth noticing, even in high-
incidence areas such as Finland. Single cases with novel mutations for CLD appear
worldwide, both in developing and more affluent countries (Table 2). In these low-
incidence countries, such CLD infrequency makes misdiagnoses highly probable.
Childhood dosing with salt substitution has increased during the last decades, but later
in life, therapy seems easily to remain insufficient. Even in our series of patients, minor
abnormalities in acid-base and electrolyte balance or in growth were present in a
respective 60% and 22% (I, Table 2). Accordingly, the current mean dose taken of Cl-,
2.8 mmol/kg/day, fell below the recommended adult dosage of 3 to 4 mmol/kg/day
(Holmberg 1986). One-fourth of our patients reported consumption of salty food,
reflecting the insufficient dosage with salt substitution. To overcome signs of inadequate
treatment—low  urinary  Cl-,  low  serum  K+, and metabolic alkalosis—we increased the
mean daily dose of Cl- in 24 (67%) patients to at least a minimum of 3.0 mmol/kg/day.
This study is, to our knowledge, the first to show that salt substitution therapy with
NaCl and KCl, proved to enable normal childhood growth and development (Holmberg et
al. 1977a), allows favorable long-term outcome in CLD. In agreement with this finding,
92% of our patients regarded their general state of health as excellent or good. Although
the diarrheal symptoms of CLD were persistent, only minor soiling problems remained in
adulthood. The patients had adjusted to their diarrheal symptoms, and only four (11%)
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reported occasional use of cholestyramine to temporarily reduce their diarrhea and prevent
soiling.
Combination therapy with NaCl and KCl seems to allow normal growth and
development in CLD even if the diagnosis is delayed and early therapy inadequate. To
support this, therapy with NaCl and KCl normalized early growth retardation in the
patients born in the 1960s, despite late-diagnosed CLD or pure KCl therapy in early
childhood or both (I, Figure 3). A common feature in those 28% of the patients with
chronic kidney disease (CKD) was, however, late-diagnosed CLD, indicating that early
contraction affects renal outcome in CLD (V, Table 1).  As evidence of the role of early
changes, onset of CLD-related renal injury in the Finnish case with ESRD was
neonatal. A probable contributor to the progression of renal injury in this patient was
inadequate salt substitution. In other patients, however, sufficient salt substitution seems
to  have  offered  protection  from major  renal  changes.  In  contrast,  the  Swedish  case  with
ESRD exhibited a critical condition with the CLD diagnosis coming only after the second
transplantation. Although the chronic tendency to hypovolemia seems to affect renal
growth in CLD (V, Figure 2), the unique finding of a solitary kidney in that Swedish case
was probably unrelated to CLD.
Our results in a series of patients suggest that the pathophysiological basis of
nephrocalcinosis, the most striking renal feature of CLD, includes NaCl and volume
depletion.  Along  the  nephron,  Ca2+ reabsorption occurs mostly through a passive
paracellular route in parallel with sodium reabsorption, Cl- movement acting as an
additional driving force for reabsorption (Friedman 1998, Stanton and Bruce 1998, Sayer
et al. 2004). Unlike in CLD, an almost universal feature in tubulopathies with
nephrocalcinosis is hypercalciuria (Sayer et al. 2004). Despite the absence of
hypercalciuria in CLD, the diarrhea-related NaCl and volume depletion (Holmberg 1986,
Melvin et al. 1999) may play a role in the pathogenesis of nephrocalcinosis. In CLD, NaCl
and fluid depletion is always accompanied by reduced GFR and even by hypotension (V,
Figure 3). As the primary determinants of saturation are excretion of calcium salts and
water (Sayer et al. 2004), in CLD, hypovolemia together with low NaCl delivery to the
thick  ascending  limb  of  Henle  and  distal  tubule  of  the  kidney  could  fail  to  provoke  an
electrochemical gradient for Ca2+ reabsorption, allowing urine supersaturation and the
formation of luminal crystals. This hypothesis could also provide an explanation of the
early findings of nephrocalcinosis in KCl-treated CLD, despite the systemic balance
(Pasternack and Perheentupa 1966, Pasternack et al. 1967, Holmberg et al. 1977b). To
further support the role of hypovolemia, urine volume predicts urinary supersaturation in
children with idiopathic urolithiasis (Lande et al. 2005), and increased water load offers
protection from crystallization in adult idiopathic stone-formers (Borghi et al. 1999).
Rapidly progressive calcification and renal failure in CLD seem to develop only in the
presence of long-lasting hypochloremic and hypokalemic metabolic alkalosis, as seen in
our  patients’  own  kidneys  and  in  their  transplants.  The  different  mutations  in  these  two
cases with ESRD suggest that renal impairment is independent of genotype. Most
probably, complex compensatory actions modulate both the onset and clinical course of
the kidney disease. A striking example of these potential compensatory mechanisms is the
Finnish boy with his diagnosis of CLD at age five. Despite his late-diagnosed disease, this
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currently 11-year-old patient has totally normal renal function. Although some effects on
renal function may emerge with age, along with episodes of metabolic imbalance, some
unidentified mechanisms are likely to modulate the individual susceptibility to CLD-
related renal impairment.
In addition to diarrhea and renal involvement, other CLD-related manifestations arose
in this study (Figure 8). CLD seems to be associated with an age-dependent increasing risk
for hyperuricemia. As in the case of renal involvement, the probable pathogenesis of
hyperuricemia involves the tendency toward chronic dehydration (Choi et al. 2005).
However, only our patient with a renal transplant (V, case 1) had developed gouty
arthritis.
As one patient had Crohn’s disease and another had a diagnosis of unspecified colitis,
CLD may be associated with an increased risk for intestinal inflammation. Whether the
elevated erythrocyte sedimentation rates in ten of our patients (28%) were related to
intestinal inflammation, or even to decline in renal function, remains unclear. As
downregulation of SLC26A3 emerges in the inflamed colonic mucosa (Yang et al. 1998,
Lohi et al. 2002b), a link between intestinal inflammation and the primary genetic defect
of CLD is possible. Despite the slightly increased risk for gastrointestinal malignancies in
one study (Hemminki et al. 1998), in this series of patients, no cancers arose.
Acute gastroenteritis (AGE) may lead to life-threatening complications in CLD due to
the associated susceptibility to rapid dehydration, hypokalemia, and alkalosis. Although
this tendency persisted into adulthood, the severe episodes became less frequent. To
prevent AGE-related dehydration, most adult patients had learned to take an extra dose of
salt substitution.
Similarly, adding salt substitution during excessive sweating may be important, as
reported by some of our patients (unpublished data). The increased concentrations of
sweat Cl- in 12% of the patients suggest a minor role for SLC26A3 in the sweat gland. As
the major protein mediating thermoregulation and salt retention through the sweat glands
is CFTR (Sato and Sato 2000), the sweat gland may be an additional site for the
interaction of SLC26A3 and CFTR (Wheat et al. 2000, Jacob et al. 2002, Ko et al. 2004,
Rossmann et al. 2005).
Of the minor medical conditions in our patients, allergic diseases including hay fever,
asthma, and atopic eczema were common but showed a prevalence comparable with that
of the general Finnish population (Huurre et al. 2004). Dental and oral health was good, in
concordance with a report of caries-protecting influence of oral salt substitution
(Myllarniemi and Holmerg 1975).
Of 16 males, four had been operated on for inguinal hernia, three of them in infancy.
That is ten times as high as the average prevalence of  hernias (Maisonet 2003) and
suggests a role for elevated intra-abdominal pressure in the pathogenesis. Additionally,
spermatoceles were more common than in the general population (Gutman et al. 1986).
Later, this study showed that formation of spermatoceles in CLD is associated with male
subfertility. Although 38% of the adult males reported infertility in the first part of the
study, no abnormalities in female reproductive capacity in CLD emerged.
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Figure 8 Clinical manifestations of CLD and known sites of human SLC26A3 expression.
2 SLC26A3 and male subfertility
The molecular basis of male infertility is heterogeneous and poorly understood. Here, we
demonstrate that CLD is associated with a unique phenotype showing accumulation of
water into the male reproductive tract, formation of spermatoceles, and subfertility.
Despite the normal spermatogenesis in CLD, male subfertility involves a low
concentration of poorly motile sperm with abnormal morphology. A striking finding of
high seminal plasma Cl- with a low pH supports a role for a primary Cl-/HCO3- exchange
defect in the male reproductive tract. In agreement with this hypothesis, we detected
SLC26A3 immunolocalization at multiple sites of the male reproductive tract: elongating
spermatids, non-ciliated cells of ED, AMRCs of the ductus epididymis, and as described
(Haila et al. 2000), of the epithelium of the seminal vesicle.
NHE3, the main SLC26A3-interacting protein of the intestine, is crucial for normal
mouse male fertility (Zhou et al. 2001). As both SLC26A3 and NHE3 were localized on
the  luminal  side  of  the  non-ciliated  cells  of  the  human  ED,  their  cooperation  in
reabsorbing NaCl at this site is putative. In particular, the accumulation of fluid into the
male reproductive tract in both males with CLD and in NHE3 knock-out mice (Zhou et al.
2001) suggests that not only the action of NHE3 but also that of SLC26A3 is essential for
the fluid reabsorption in the ED (Clulow et al. 1998, Hansen et al. 2004). A lack of
function  of  SLC26A3 may,  similarly  to  that  seen  in  the  CLD intestine  (Holmberg  et  al.
1975, Melvin et al. 1999, Lamprecht et al. 2002), lead to secondary inhibition of the
Na+/H+ exchange through NHE3. Thus, defective NHE3 function may further enhance the
accumulation of fluid into the ED, the luminal dilation, and the dilution of the epididymal
sperm in CLD (Zhou et al. 2001).
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The unique finding of large bilateral spermatoceles in CLD suggests that defective
SLC26A3-mediated anion transport may be an important contributor to the formation of
spermatoceles. The pathophysiology of spermatoceles, including aging and inflammatory
changes, remains mostly undetermined (Rubenstein et al. 2004). As spermatoceles are,
however, cystic dilations of the ED region, defective fluid reabsorption and increased
intraluminal pressure at this site may play a role in the pathogenesis.
Concerning human male infertility, the gene of interest is CFTR. Its  variants  are
associated with various infertility-related phenotypes from CF-associated CBAVD to
idiopathic oligozoospermia even in carrier males (Chillon et al. 1995, van der Ven et al.
1996, Meschede et al. 1997, Schulz et al. 2006). The CFTR channel has distinct abilities
involving Cl- channel activity and HCO3- secretion, the latter probably being mediated by
the anion transporters of the SLC26 family (Ko et al. 2002, Ko et al. 2004). Interestingly,
the ability to activate HCO3- transport is even more sensitive to CFTR mutations (Choi et
al. 2001b). In the milder forms of CF with abnormal HCO3- secretion but normal Cl-
channel activity, the only manifestation can be male infertility (Meschede et al. 1997).
This suggests that rather than Cl-, the crucial ion for normal male fertility is HCO3-.
Both  SLC26A3  and  CFTR  were  detected  in  the  non-ciliated  cells  of  the  ED,  the
AMRCs of the epididymis, and the ductal epithelium of the seminal vesicle. This suggests
that  SLC26A3  may  act  together  with  CFTR  as  a  ductal  HCO3- secretor  in  the  male
reproductive tract, similarly to that function proposed for the pancreatic duct and small
intestine (Greeley et al. 2001, Ko et al. 2002, Ko et al. 2004). Although data on the
transporter actions in different cell types of the male reproductive tract are lacking, HCO3-
directly affects sperm motility, and after ejaculation, sperm capacitation (Okamura et al.
1985, Wang et al. 2003). Therefore, some features in CFTR-associated male infertility
may actually implicate the loss or reduced activity of epithelial HCO3- secretion through
SLC26A3.
In men with classical CF, the primary cause of their low seminal plasma pH (Kaplan et
al. 1968) is the absence of or anomalies of the seminal vesicles, which normally secrete
HCO3--rich fluids to allow the viability and motility of spermatozoa after ejaculation
(Anguiano et al. 1992). Although low seminal plasma pH is a rare finding in conditions
other than CF, decreased levels of HCO3- may be associated with male infertility
(Okamura et al. 1985). Our results, showing a low pH for seminal plasma in CLD, suggest
accordingly that decline in pH might be the most important contributor to the poor sperm
motility in CLD.
To make the puzzle more complex, even the normal seminal plasma pH values in our
series were associated with equally poor motility of sperm. This suggests that factors other
than pH only, for instance high seminal plasma Cl- and dilution of epididymal sperm,
disrupt  the  sperm motility  in  CLD,  as  well.  Most  probably,  diverse  actions  of  epithelial
transporters—such as those of SLC26A3, NHE3, and CFTR—induce complex regulatory
networks and produce distinct micro-environments in the male reproductive tract. These
local circumstances may further regulate the net reabsorption and secretion, and affect
sperm maturation and motility.
In the ED of the single patient with CLD, SLC26A3 and CFTR immunoexpression
was absent, despite the expression of NHE3. The testicular tissues from two patients with
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CLD showed, however, expression profiles identical to those of controls for both
SLC26A3 and CFTR. In agreement with this finding, the V317del-mutated SLC26A3
shows some apical and strong cytoplasmic signals in the instestinal epithelium for both the
SLC26A3 mRNA and protein (Hoglund et al. 1996b, Haila et al. 2000). Therefore, the lack
of SLC26A3 and CFTR expression in the ED of our CLD patient may be secondary to his
luminal dilation and spermatocele formation, rather than being a primary finding. As no
CLD samples were available for expression studies in other tissues, such as ductus
epididymis and seminal vesicle, any final assessment of CLD-related expression profiles
remained impossible.
The role of the expression of SLC26A3 and CFTR observed in the elongating
spermatids remains unclear. In CF, inconsistent histological findings
(hypospermatogenesis, increased number of dysmorphic spermatozoa) of spermatogenesis
are probably secondary to CBAVD (Denning et al. 1968, Kaplan et al. 1968, Mak et al.
2000). Limited data support, however, the presence of CFTR in both the human and rat
testis (Tizzano et al. 1994, Larriba et al. 1998, Gong et al. 2001). Although SLC26A3—
even together with CFTR—may play a primary role in developing spermatozoa,
histologically normal spermatogenesis in CLD allows assisted reproductive technologies
to treat infertility. Limited clinical experience in CLD males shows, however, that
fertilizations in vitro might be highly challenging (unpublished data).
An interesting prospect is whether some heterozygous SLC26A3 variants might,
similarly to that seen for CFTR mutations (van der Ven et al. 1996, Schulz et al. 2006),
account for male subfertility without causing the intestinal phenotype of CLD. This seems
to be improbable in the case of the Finnish founder mutation V317del, however, as no
evidence of any fertility-related problems has arisen among the fathers of our patients.
Despite this fact, our initial results suggest that some rare variants of the SLC26A3 gene
may be more common in men with idiopathic infertility than in their normozoospermic or
fertile controls (unpublished data).
Finally, the unpublished observations of reduced fertility in SLC26A3-deficient mice
(Schweinfest et al. 2006) establish the crucial role of SLC26A3 in both human and mouse
male fertility (personal communication). That CFTR knock-out mice exhibit normal
reproductive function (Snouwaert et al. 1992), but knock-out mice for SLC26A3 or NHE3
are subfertile or infertile (Zhou et al. 2001, Schweinfest et al. 2006), supports a crucial
role for the functional SLC26A3 in the male reproductive tract.
3 Variable effects of oral butyrate in CLD
Because the SLC26A3 gene responsible for CLD encodes for the major apical anion
transporter of the colon (Moseley et al. 1999, Schweinfest et al. 2006), options to resolve
the  diarrheal  symptoms  of  CLD  have  been  limited.  An  Italian  case  report  showed,
however, that administration of oral butyrate normalized the stool pattern in an
11-year-old male patient with CLD (Canani et al. 2004). That study prompted us to study
the influence of butyrate on diarrhea among Finnish patients with CLD.
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The short-chain fatty acid butyrate is the most essential end-product of bacterial
carbohydrate fermentation in the colon and is the principal nutrient for colonocytes. It
maintains the normal cell population and inhibits tumorigenesis through multiple
mechanisms (Topping and Clifton 2001). Regarding CLD, the most important function of
luminal butyrate is its potential to modulate colonic epithelial ion transport. The net effect
of increased electroneutral absorption of NaCl and fluid occurs mostly through activation
of the Na+-H+ exchangers NHE2 and NHE3, whereas the direct effect of butyrate on the
apical membrane Cl-/HCO3- exchange is actually inhibitory (Yun et al. 1993, Vidyasagar
et al. 2005).
That only one patient in our pilot study showed a modest response to oral butyrate was
surprising. Even more strikingly, the distinct pattern of laboratory measurements in this
butyrate-responsive patient consistently differed from that of the other patients—despite
the comparable baseline concentrations of electrolytes (IV, Figure 1). Actually, the
clinically non-responsive patients (n=4) demonstrated signs of salt depletion in CLD,
including decreased renal excretion of NaCl and a tendency to alkalosis. These changes
supported, despite the slightly inconsistent fecal measurements, butyrate-induced loss of
intestinal NaCl and fluid.
This study shows that responses to oral butyrate in CLD are variable, ranging from
beneficial to slightly harmful. Adding our data to the Italian butyrate-responsive case with
two different SLC26A3 mutations, Q495H and A547E (Canani et al. 2004, Cardillo 2005),
suggests for the first time that genotype-phenotype differences may affect responses to
diarrhea-reducing therapies in CLD. In the case of butyrate, diverse responses seem to
arise  even  within  the  same  genotype  for  CLD,  as  seen  in  our  patients  with  the
homozygous V317del mutation. Lack of an oral slow-release form of butyrate is likely to
allow partial absorption even in the small intestine, potentially resulting in variable
colonic  concentrations  of  butyrate,  and  in  part  explaining  the  diversity  of  responses
(Topping and Clifton 2001).
In the case of CFTR mutations, the ability of butyrate to partially restore the function
of the mutated CFTR channel depends on the genotype (Kerem 2006). Although CFTR
mutations and the 5T allele were excluded from this study, the modulatory action of CFTR
may contribute to the dramatic butyrate response in the one Italian case. It is possible that
the A547E-mutated STAS domain in that patient fails to interact with the R domain of
CFTR (Lamprecht and Seidler 2006). This could result in reduced baseline activity of
CFTR  (Ko  et  al.  2004),  explaining  the  atypically  severe  diarrhea  in  that  patient.
Accordingly, the improved action of CFTR caused by butyrate may account for the
dramatic butyrate response in that single case. As the sequencing of the whole coding
region of SLC26A3 in our butyrate-responsive patient revealed an intact STAS domain,
however, other genes are likely to modulate the actions of butyrate.
This study uncovered important safety issues. The slight butyrate-induced
hyperuricemia in our four butyrate-nonresponsive patients (unpublished data) was
probably related to volume depletion (Choi et al. 2005), but butyrate-induced
hyperuricemia (Gore et al. 2001) and the increased risk for hyperuricemia in CLD are
worth noticing. More important, the increased fecal concentrations of calprotectin and
?1-antitrypsin after butyrate deprivation in the butyrate-responsive patient suggest that the
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dosage of butyrate should be gradually tapered before being halted. As downregulation of
SLC26A3 mRNA and upregulation of CFTR are characteristic of the inflamed colonic
mucosa (Yang et al. 1998, Lohi et al. 2002b), and the increased risk for intestinal
inflammation appears both in CLD and CF (Bruzzese et al. 2004), the CLD colon may be
especially vulnerable to modulatory actions of butyrate, and to butyrate deprivation.
Finally, the slightly increased risk of colon carcinoma in CLD (Hemminki et al. 1998)
makes monitoring of intestinal inflammation in any future trials with potential diarrhea-
reducing agents of CLD even more important.
4 SLC26A3 in the human kidney
Several of the SLC26 family members mediate renal anion exchange (Table 1). Of them,
SLC26A1 is located in the basolateral and SLC26A6 on the apical epithelium of the
proximal tubule of the kidney. At least SLC26A6 possesses essential mechanisms for
anion transport in the proximal tubule, as its defective function causes mouse urolithiasis
(Jiang  et  al.  2006,  Sindic  et  al.  2007).  In  the  intercalated  cells  of  the  cortical  and  outer
medullary collecting duct, respectively, are located apical SLC26A4 and basolateral
SLC26A7. These probably contribute to the regulation of both acid-base homeostasis and
blood pressure. Of the other SLC26 family members, SLC26A2, SLC26A9, and SLC26A11
mRNA are expressed in the kidney (Table 1).
Adding the data on variable levels of SLC26A3 mRNA and protein expression in the
kidney, our results suggest a minor role for SLC26A3 in renal physiology. Unlike this
study, many previous studies have failed to show SLC26A3 expression in the kidney,
either in humans or in mice (Hoglund et al. 1996b, Haila et al. 2000, Wang et al. 2005).
Similarly, microarray data on SLC26A3 expression are inconsistent, with only a few
human kidney samples showing expression of SLC26A3 RNA
(http://www.ncbi.nlm.nih.gov/geo) (Edgar et al. 2002).
One possibility for the discrepancy observed in renal SLC26A3 expression is its highly
limited  expression  on  the  apical  membrane  of  the  distinct  intercalated  cells  of  the  CNT
and CCD. Another possibility is that compensatory up- or downregulation of the
expression occurs in response to metabolic imbalance, as shown for mouse SLC26A4 and
SLC26A7.  Systemic  Cl- depletion upregulates renal SLC26A4 in the type B intercalated
cells of mice (Quentin et al. 2004, Vallet et al. 2006), whereas hypokalemic or hypertonic
medium in cell cultures drives SLC26A7 from endosomes to the basolateral membrane of
the type A intercalated cells (Xu et al. 2006), promoting anion exchange. If similar
upregulation of SLC26A3 occurred in the presence of some common metabolic imbalance,
it could in many respects explain the inconsistent data on renal SLC26A3 expression. To
support this hypothesis, our results exemplified highly variable levels of both renal
SLC26A3 mRNA and protein. Although the one paraffin-embedded CLD-kidney sample
showed no staining for SLC26A3 in immunohistochemistry, the lack of other CLD
samples made overall assessment of this finding difficult.
An attractive and likely candidate for the regulation of renal SLC26A3 expression and
function  may  be  the  Cl-/HCO3- exchanger SLC26A4. This protein shares the closest
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structural similarity (60%) with SLC26A3 (Mount and Romero 2004), and has a similar
site  of  expression  in  the  kidney  CNT  and  CCD  (Royaux  et  al.  2001),  where  the  final
regulation of acid-base and NaCl balance occurs. Although SLC26A4 is the major
Cl-/HCO3- exchanger in both the type B and nonA-nonB intercalated cells (Schuster and
Stokes 1987, Soleimani et al. 2001), renal manifestations or metabolic alkalosis are neither
features of SLC26A4 deficiency in human disease pendred syndrome (Everett et al. 1997),
nor are they characteristic of SLC26A4-deficient mice (Royaux et al. 2001). Similarly, the
loss  of  functional  SLC26A3  in  CLD  is  not  associated  with  renal  Cl- wasting. These
disease-associated features and the similar expression patterns of SLC26A3 and SLC26A4
raise  the  question  as  to  whether  a  lack  of  the  function  of  one  transporter  could  be
compensated for by the corresponding function of the other. To support this hypothesis,
treated CLD was associated with normal electrolyte and acid-base balance, but strikingly,
with alkaline urine in 37% of the patients. In CLD, upregulation of renal Cl-/HCO3-
exchange, possibly that of SLC26A4, is therefore likely to occur. As upregulation of renal
SLC26A4 in mice occurs merely in response to Cl- depletion (Quentin et al. 2004, Vallet et
al. 2006), the potential contributor in CLD may be the intestinal loss of Cl-. Thus, in the
presence of minor Cl- depletion in CLD, compensatory activation of SLC26A4 may
inhibit the development of hypochloremia and metabolic alkalosis.
To further support our hypothesis, corresponding reciprocal upregulation of SLC26A3
occurs in the pancreatic duct of SLC26A6-knockout mice, enabling normal HCO3- and
fluid secretion (Ishiguro et al. 2007). In the presence of the major anion exchanger
SLC26A6, expression of SLC26A3 is low if not absent, however (Hoglund et al. 1996b,
Ishiguro et al. 2007). In agreement with this finding, in CLD, pancreatic manifestations
are non-existent.
Our study shows that CLD-related renal injury affects both the patients’ own kidneys
and the patients’ transplants. Therefore, renal SLC26A3 may play only a minor role in
homeostasis. More studies are necessary to assess the complex renal process and
regulation of the Cl-/HCO3- exchange,  the entity to which several SLC26 transporters
contribute.
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Conclusions and future prospects
This study reveals that salt substitution therapy with NaCl and KCl will allow a favorable
long-term outcome in CLD. In untreated or poorly treated cases, the most severe
complication  is  renal  involvement,  which  can  ultimately  lead  to  ESRD  and  renal
transplantation. The main contributors to the renal injury, and to small size kidneys, are
chronic hypovolemia and metabolic imbalance. Although this study, to our knowledge,
demonstrates  for  the  first  time  expression  of SLC26A3 in the human kidney, the post-
transplant recurrence of renal injury in CLD demonstrates the role of metabolic changes,
rather than direct transporter modulation, in the pathogenesis of renal involvement.
Despite the salt substitution therapy, diarrhea in CLD is persistent. Based on our pilot
study, modulation of the intestinal ion transport by oral butyrate is unlikely to replace the
lost Cl-/HCO3- exchange activity characteristic of CLD. Our results propose, however, that
responses to diarrhea-reducing therapies in CLD vary, even within the same genotype. In
the series of Finnish patients with CLD, a slight response to oral butyrate in only one
patient supports no further trials. The dramatic response in the single Italian case indicates,
however, that butyrate action may be beneficial in some cases with CLD. Therefore, only
studies  among  patients  with  several  different  genotypes  for  CLD  can  reveal  whether
butyrate has, similar to that seen in CF, efficacy for patients with certain genotypes only.
The most interesting novel finding of this study is CLD-associated male subfertility.
Based on our data, the underlying cause may be the defective SLC26A3-mediated
Cl-/HCO3- exchange in the male reproductive tract.  In the ED of the testis,  disruption of
SLC26A3, probably resulting in inhibition of NHE3 and modulation of CFTR, may lead
to  poor  reabsorption  of  water  and  NaCl,  aberrant  secretion  of  HCO3-, and further to the
tendency to form spermatoceles. Acidic, hypo-osmotic, Cl--rich seminal plasma is likely
to further inhibit normal sperm maturation and motility. Disruption of SLC26A3 in the
epididymis and seminal vesicle, perhaps together with CFTR, may similarly affect sperm
maturation and motility.
Normal testicular histology provides possibilities for assisted reproductive
technologies to treat male subfertility in CLD. Clinical experience suggests, however, that
difficulties may arise even in the case of in vitro fertilization. Fortunately, some Finnish
men with CLD have succeeded in producing a child, even without assisted reproduction.
Further studies should elucidate the role of SLC26A3 during spermatogenesis, and the
success of infertility treatments in CLD. In addition, a probable association of rare
SLC26A3 variants  with  the  complex  trait  of  idiopathic  male  infertility  needs  to  be
clarified.
It is worth remembering that our results stem from a highly homogenous population of
Finnish patients with an identical genetic background for CLD. Therefore, future work is
necessary to assess phenotypical differences, if any, in CLD. At least in the knock-out
mouse model, profuse diarrhea and male subfertility seem to emerge similarly to that seen
in the human disease. It is therefore likely that patients with CLD share, independent of
genotype, the main clinical features that we describe in this study.
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